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Chapter 1. 
General Introduction 

INTRODUCTION 
Rhinitis is a very common disorder. Most people suffer from an infectious rhinitis at least 
once a year. The symptoms usually disappear within a week. The patients with chronic 
rhinitis pose a much greater problem. At least 10 % of the general population are affected by 
a chronic allergic or non-allergic non-infectious rhiilltis (l). The impact of the nasal 
complaints such as in rhinitis is often underestimated. Bousquet and Juniper demonstrated 
that the impact of the disease on the quality of life is greater in rhinitis than in asthma patients 
(2-4). There is no generally accepted system for the definition, classification and terminology 
of rhinitis (5). A distinction can be made between rhinitis of known and unknown etiology. 
Known causes for rhinitis can be subdivided in mechanical Jactors (e.g. septal deviation, 
foreign body,), injections (viral, bacterial, fungal), miscellaneous causes (e.g. rhinitis 
medicarnentosa, pregnancy, cystic fibrosis) and allergy. Syndromes of unknown etiology 
include non-allergic non-infectious perennial rhinitis (NANIPER), nasal polyposis and non-
allergic rhinitis with eosinophilia (NARES). 
The subject of this thesis is the pathogenesis and treatment of NANIPER. As this teml 
suggests the disorder is diagnosed through the exclusion of the known causes for rhinitis. 
Available studies are often difficult to compare. Different authors use different methods to 
exclude "the known causes". The patients are sometimes presented in a study as NANIPER 
patients without further specification. The way in which an allergic pathogenesis is excluded 
varies from skin prick tests, senllu testing for specific IgE, total IgE, nasal provocation tests 
or a combination of these methods. To exclude infection some authors rely on the history 
(chronicity of the illness, lack of purulent secretions and or the classic symptoms of acute 
rhinosinusitis), some rely on laboratory parameters (sedimentation rate, white blood cell 
count, nasal smears), others use negative radiological findings (noffilal sinus X-ray or CAT-
scan), all with or without the use of a nasal symptom score. 
Studying the pathophysiology and treatment ofNANIPER , we have to consider the nature of 
the diagnosis by exclusion, the variability of Hpatient phenotype" reported in the literature, 
and the dearth of "hard data". A clear definition of, and a lucid method for the selection of 
NANIPER patients are needed. Even then we will inevitably be confronted with various 
nosologic entities all presenting as NANIPER. Unfortunately these difficulties have 
precluded many investigators from studying the pathophysiology of this disorder. On the 
other hand, the prevalence and the impact of this disorder on the quality of life have 
stimulated researchers to investigate treatment modalities. 
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DEFINITION 
The working definition ofNANIPER as suggested by Mygind (I) is as follows: 
"Patients with NAN/PER suffer from chronic symptoms stich as nasal congestion, 
rhinorrhoea, posterior nasal drainage, sneezing, itching and occassionaly pain over the 
sinuses. The etiology is unknown, and the diagnosis of this disorder is made by exclusion" 
NANIPER, or vasomotor rhinitis, can be subcategorized according to the presence of nasal 
eosinophilia. Patients with a nasal smear showing more than 25% eosinophils are classified as 
non-allergic rhinitis with eosinophilia syndrome (NARES) (6). 
NANIPER has to be distinguished from hyperreactivity. Nasal hyperreactivity or 
hyperresponsiveness refers to an increased sensitivity to non-specific stimuli or irritants. 
Nasal symptoms, related to hyperreactivity (sneezes, rhinorrhea and/or nasal blockage) occur 
on exposure to daily-life stimuli such as dust particles, change of temperature, tobacco 
smoke, perfumes and paint smells (7). Hyperreactivity can be observed in allergic rhinitis, 
infectious rhinitis and NANIPER. 
EPIDEMIOLOGY 
General popUlation prevalence 
Non-allergic non-infectious rhinitis is a common disorder (5). Its exact point prevalence is 
unknown. MaIm reported (Rome. ERS 1992) a prevalence of 5-10% ofNANIPER in Malmo 
City, suggesting the same general population prevalence as allergic rhinitis. 
General practitioner prevalence 
Crobach studied 365 patients suffering from rhinitis, in a general practice; 20 to 60% were 
diagnosed as NANIPER (8). 
Specialist prevalence (ENT, allergy) 
Annually an average of 350 patients (1995-1997) are referred to the outpatient clinic of the 
department of Otorhinolaryngology of the University Hospital Dijkzigt suffering from either 
allergic rhinitis (50%) or NANIPER (50%). In the department of Allergy in the sanle hospital 
2661 patients suffering from rhinitis were examined in a period of foUl' year. The percentage 
of non-infectious non-allergic rhinitis was 14% (380). NANIPER is reported to account for 
30% to 70% of cases of chronic perennial rhinitis (9). Settipane reported a prevalence of 61 % 
for NANIPER in a group of chronic perennial non-allergic rhinitis patients. In the same group 
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31 % of patients suffered from NARES (10). This agrees with a report by Mullarky who 
reported NANIPER to be almost twice as common as NARES (II). 
Jessen published on the natural course of NANIPER and reported a spontaneous 
disappearance in 20% and a spontaneous improvement of nasal complaints in 36% of patients 
over a ten-year period (12). 
PATHOGENESIS 
Proposed pathophysiologic mechanisms for non-allergic rhinitis include the possibility of a 
chronic inflammatory disorder of antigenic or neurogenic nature, as well as the possibility of 
a functional neuronal disorder. 
Neurogenic aspects of the pathogenesis ofNANIPER. 
Parasympathetic/sympathetic system imbalance. 
In 1959 Malcomson stated that NANIPER was caused by autonomic imbalance (13). 
Normally, base line sympathetic tone provides constant alpha and beta adrenergic receptor 
stimulation (table 2). The marked alpha-l predominance in nasal blood vessels leads to 
vasoconstriction (14). Underactivity of the sympathetic nervous system leads to nasal 
obstruction (15). 
Parasympathetic effects on blood vessels are minimal under basal conditions. Stimulation of 
cholinergic nerves leads to hypersecretion and dilation of mainly resistance vessels (nasal 
blood flow) and to some extent capacitance vessels (nasal patency). Overactivity of the 
parasympathetic system leads to rhinorrhea (is). However, van Megen, in a group of 4 
patients, was unable to show significant differences in alpha-2, alpha-l and heta-
adrenoreceptors between controls and vasomotor rhinitis patients (16), 
Parasympathetic system Sympathetic system Peptidergic system 
Acetylcholine (nor)-adrenaline Substance P 
VIP NPY CGRP 
PHI NKA 
GRP 
Secretion Vasoconstriction Vasodilatation 
Vasodilatation Increased permeability 
Exocrine secretion 
Table 2. The nerve system of the nose: transmitters and effects. 
Non-adrenergic-non-cholinergic system: peptidergic system. 
Wolf suggested that NANIPER could be the result of an "over-active" non-adrenergic non-
cholinergic system (table 2) (17). Stimulation of sensory neurons results in sensory nasal 
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changes, rhinorrhoea (I8), nasal blockage and sneezing. Sensory neural stimulation may 
produce these effects either through a central neural reflex, associated with efferent 
parasympathetic neurotransmission, or via anti·dromic release of neuropeptides from sensory 
neurons (figure I) (19, 20). This hypothesis was corroborated by the findings of Lacroix, who 
reported an increased concentration of neuropeptides in a group of chronic non-allergic 
rhinitis patients (21), improvement of symptoms by local treatment of capsaicin giving a 50% 
reduction in CGRP-Li content in nasal biopsies (22), and a correlation between symptom 
intensity and CGRP-Li concentration in nasal mucosa (23). 
Hyper- or dys-esthesia at CNS level. 
Sanieo has suggested that it is reasonable to raise the possibility of sensory imbalance that is 
characterized by dys- or hyper-esthesia at the CNS level (25). 
Antigenic 
Local occult allergy 
Another theory concerning the pathogenesis of NANIPER includes a local, occult allergy 
(10). The diagnosis of NANIPER is made by exclusion and an allergy test is not 100% 
sensitive. Moreover systemic manifestations, such as a positive skin prick test or RAST, of 
atopic disease might he missed because the nose is a small shock organ. However, one has to 
consider the suggested NANIPER population prevalence of 5-1 0%. 
Food allergy 
Food allergy is also considered as a potential pathophysiological factor in NANIPER. In 
adults, ifrhinitis is the only manifestation, food allergy is not very likely (4). 
Non-allergic rhinitis with eosinophilia syndrome 
It seems reasonable to suggest that NARES is a pathophysiological entity differing from 
NANIPER because of its association with nasal polyposis and good response to local steroid 
therapy (II, 26). 
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Figure I. Simplified scheme ofaulonomic and peptidergic innervation of the nasal mucosa, 
Irritation initiates an afferent signal via the maxillary nerve and trigeminal ganglion into the medulla oblongata, 
where it is relayed to the cortex. An efferent signal is generated to the preganglionic parasymphathetic neurons 
which results in a signal to the sphenopalatine ganglion cells. The final result is a strong parasympathetic signal 
into the nasal mucosa which gives rise to increased secretion and vasodilatation. The initial irritation also 
induces the release of mediators (ncuropeptides) from sensory nerves in the nasal mucosa which results in 
increased vasodilatation, vascular penneability and secretion (24). This is known as the anti-dromic reflex. In 
NANIPER patients the last mechanism may be "overheated". 
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TREATMENT MODALITIES 
Therapy for NANIPER is symptomatic and includes phamlacotherapy and surgery. 
Pharmacotherapy in NANlPER 
Topical sympathicomimetica (xylometazoline e.g.) provide relief only for a short period after 
which rhinitis medicamentosa will coexist with the original disease (27). 
Systemic svmphatlcomimetic decongestants are not allowed in the Netherlands and seem to 
have many side effects (28). 
Patients who complain of excessive rhinorrhea are successfully treated with the local 
anticholinergic agent ipratropium bromide (Atrovent) (29-38). 
The first studies showing efficacy of topical steroids in NANIPER were performed in the late 
seventies and in the beginning of the eighties (9, 38-41). Recent studies using f1uticasone 
propionate aqueous nasal spray for the treatment of NANIPER have shown an efficacy 
comparable to the efficacy of topical steroids in allergic rhinitis (42, 43). Philips, in 1995, 
stated however, that although some clinical efficacy has been demonstrated in non-allergic 
non-infectious perennial rhinitis (NANIPER), these agents often do not provide the sarne 
relief as they do in allergic rhinitis (44). 
Capsaicin is the pungent agent in red peppers. Its mode of action is well documented in 
rodents, where it affects mainly the thin umnyelinated sensory nerve fibers. It causes initial 
stimulation (with release of endogenous neuropeptides), followed by desensitization to 
capsaicin and other sensory stimuli (45). With higher doses long term functional or even 
morphological ablation of the thin sensory neurons occur (46). Several not placebo controlled 
studies have been published showing that capsaicin desensitization might be an important 
therapeutic modality in NANIPER (22, 47-49). 
SurgelY in NANlPER 
Surgical procedures for NANIPER aim to either modify the size of the inferior turbinate or to 
derive the nasal mucosa of its autonomic supply. The surgical scalpel, chemical sclerosing 
solutions, electrocautery, cryosurgery, snake venom and laser surgery have all been reported 
to diminish obstruction complaints (50-64). The duration of effectiveness is 6 months to 
several years (14). The aim of tltis therapy is to diminish hyperfunction of glandular and 
vascular elements while preventing the kind of destruction that impairs nonnal mucosal 
functions such as humidification, mucosal transport and nasal passage. Adhesions, atrophic 
rhinitis and even blindness have been described as complications of the former therapies. 
Golding-Wood described the effect of vi dian neurectomy (65, 66). This procedure is effective 
in relieving excessive secretion but not the obstruction. Both parasympathetic and 
sympathetic fibers are interrupted. The net effect is anticholinergic. Grote concluded that 
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vidian neurectomy was not the panacea it was claimed to be, since renervation would occur 
(67). This was corroborated by several authors (56, 57). 
STUDY DESIGN; OBJECTIVES 
This study focuses on answering the following questions: 
I. Can we accurately define, select, and study a group ofNANIPER patients? 
2. Is NANIPER a chronic inflammatory disorder, and if so, are inflammatory cells involved 
in the pathogenesis ofNANIPER? 
3. Are local steroids effective in NANIPER? Can we explain tllis effect? Can we discern 
subgroups according to the response to steroids? 
4. Is local capsaicin effective in NANIPER? What could be the working mechanism? 
In chapter 2 the selection criteria for NANIPER are fonnulated. Using nasal biopsies, the 
involvement of inflanunatory effector cells, the possibility of local allergy, and 
neurogenically induced mast cell degranulation are studied. Nasal brushes are taken to 
establish the NANIPERINARES relation. 
In chapter 3 the patient and control group are extended and, using nasal biopsies, 
inununocompetent regulatory cells are studied. 
Chapter 4 describes the effect of f1uticasone propionate aqueous nasal spray on nasal 
complaint scores and cellular infiltrates in NANIPER patients. 
Chapter 5 deals with the effect of capsaicin on nasal complaints and inflammatory mediators 
in NANIPER patients. 
Chapter 6 describes the effect of capsaicin on inflammatory cells in the nasal mucosa and 
nerve tissue. 
In chapter 7 the experiments are summarized. The role of immunocompetent cells in 
NANIPER are discussed and the therapies are evaluated. 
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Chapter 2 
Mast Cells, Eosinophils and 19E-positive Cells in the Nasal Mucosa 
of Patients with Vasomotor Rhinitis. 
An Immunohistochemical 8tudy 
H.M. BIom, T Godthelp, W.J. Fokkens, A. KleinJan, A.F. Holm, Th.M. Vroom, E. Rijntjes. 
Eur Arch Otorhinolaryngol (1995) 252 (supp!. I): 833-S39. 
SUMMARY 
Forty patients suffering of NANIPER were carefully selected on the basis of inclusion and 
exclusion criteria proposed by Mygind and Weeke. Nasal biopsy specimens were taken in the 
patient group as well as a group often controls. Brush cytology was also taken in the NANIPER 
group. Inflammatory cells were identified and counted in the nasal mucosa with the use of 
immunohistochemical techniques and a panel of monoclonal antibodies. Eosinophils were 
studied with the use of BMKI3, EG2, and Giemsa. Mast cells were studied with anti-chymase 
(B7), anti-tryptase (G3) and toluidine blue. Sections were stained with IgE as well. There was no 
significant difference in the number of eosinophils, mast cells and IgE-positive cells between the 
two groups. Additionally in contrast with other reports, in sections that were double-stained with 
anti-chymase and anti-tryptase, single chymase positive cells were found. 
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INTRODUCTION 
Rhinitis is subdivided into a munber of different entities, one of which is non~alIergic non-
infectious perennial rhinitis (NANIPER) (12). Tills tenn usually describes a chronic type of 
rhinitis with nasal congestion, rhinorrhoea and sneezing for which no plausible explanation can 
be found. In 1981 NANIPER was subcategorized based on nasal eosinophilia and the tenn 
"NARES" (non-allergic rlnnitis with eosinophilia syndrome) was introduced (7). 
By its nature as a diagnosis by exclusion, NANIPER represents a heterogeneous group of 
pathophysiological conditions. Faced with tills group of patients with non-atopic nasal 
complaints, we excluded all patients with systemic, medical. and anatomical disorders that could 
explain complaints of rhinorrhea, sneezing, and nasal obstruction. TIus group with 
lUlexplainable nasal complaints was then homogenized on the basis of a daily record chart on 
which patients had to reach a minimwn symptom score. The minimwn was set using as a basis 
the defInition of rhinitis put forward by Mygind and Wihl (25) in 1985. In affected patients 
periods of nasal discharge, sneezing and congestion had to persist for an average of at least 30 
minutes to 1 hour per day. 
Since NANIPER, according to prevailing theory, is thought to be the result of a neurogenic 
disorder (8), various authors have focussed on the neurogenic system by studying, for exanlple, 
nasal mucosal innervation or neuropeptide distribution (26). Others have examined functional 
aspects using such provocational agents as histamine and metacholine (5), neuropeptides (26), 
and non-phannacological agents such as cold, dry air (23), saline solutions and iso-osmolar 
ultrasound mist. Different therapeutic regimens including such treatments as topical steroids 
(18), ipratropium bromide (1), and various surgical interventions (9,16,19) have been studied as 
well. 
In the present study we investigated the cellular infIltrates in the nasal mucosa of patients with a 
known NANIPER. To our knowledge this subject has not been addressed before. It is well 
known that in atopic rhinitis, for exanlple, cells such as eosinophils, mast cells, antigen 
presenting cells and T-cells present in the nasal mucosa are involved in the pathogenesis and 
sustaining of this disorder (4.11). To study the cellular infIltrates in the nasal mucosa we took 
brush samples from NANIPER patients and biopsy samples from both NANIPER patients and 
controls. Biopsies were then studied for the presence, localization, and activation state of 
eosinophils as well as the occurrence and localization of mast cells and other surface 
IgE-positive cells. 
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MATERIALS AND METHODS 
Patients were studied from 1988 to 1992 in the outpatient ENT Department of Leyenburg 
Hospital in The Hague, the Netherlands. Patients were admitted to the study if they had a history 
of nasal complaints such as nasal obstruction, sneezing and rhinorrhea for a period of more than 
1 year and these symptoms could not be attributed to an atopic rhinitis, nasal or paranasai sinus 
infection, anatomical disorders affecting nasal function, pregnancy or lactation and/or systemic 
disorders (Table I). 
Inc/llsioll criteria 
- Age between 16 and 65 years 
- Negative skin prick test and negative RAST score 
- Symptoms for more than I year 
- A cumulative score of5 or more for the following nasal parameters: 
blockage, clear discharge and sneezing for at least 7 ~a'ys during a period .of 14.days. 
Exclusion criteria 
- The use of systemic Of inhaled corticosteroids within the previous month 
- The use of inhaled sodium cromoglycate or nedocromil sodium within the previous month 
- The use of astemizole within the previous month 
- Inability ofthe patient to stop taking thempy affecting nasal function 
- A serious andfor unstable disease 
- Nasal surgery within the previous 3 months 
- Significant anatomical abnonnalities affecting nasal function 
- Nasal polyps ofa history of nasal polyps 
- Nasal or paranasal sinus infection 
- Abnonnal sinus X-ray 
- Pregnancy or lactation 
- AbnomIallabomtory results for: 
blood: Na, K, Ca, total protein, albumin, urea creatinine, bilirubin, alkaline, phosphatase, aspartate 
aminotransferase, alanine aminotransferase, gamma glutamyl transpeptidase, hemoglobin, red blood cell count, 
plasma cell volume, mean corpuscular volume, platelets, total white blood cell count, neutrophils, lymphocytes, 
monocytes, eosinophils, basophils 
urine: blood, protein, glucose 
- Abnonnal findings at physical examination 
Table I Criteria for the selection of patients with non-allergic non-infectious perennial rhinitis 
Patients with nasal polyps were also excluded since they may belong to a different 
pathophysiological group and their polyps may contribute to a higher symptom score for nasal 
blockage and/or rhinorrhea. Of those individuals selected, 155 patients scored their nasal 
complaints for a period of2 weeks, using our daily record their nasal complaints for a period of 
2 weeks using our daily record nasal complaints for a period of 2 weeks using our daily record 
chart (DRC) (Table 2). The duration of complaints during tile day was then used as the prime 
criterion for further study (25). Patients had to have a clUnulative score of 5 or more for the 
following nasal parameters: blockage, clear nasal discharge, and sneezing for at least 7 days 
eligible for our study and participated under conditions ofinfonned consent. 
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Possible scores on the daily record chart 
Nasal blockage: 
(not being able to breathe freely through the nose) 
Clear nasal discharge: (runny nose) 
Sneezing 
Coughing 
Mucus production: 
(yellow, green or brown) 
o absent 
1 = between O-Ih per half day 
2 = between 1-2 h per half day 
3 = more than 2 h per half day 
o = absent 
1 = less than 5 periods per half day 
2 = between 5-l0 periods per half day 
3 = more than 10 periods per half day 
o = absent 
I = present 
Table 2. Scheme of the daily record chart for defming nasal symptoms in patients with NANIPER (VMR). 
A nasal brush sample for cytology and a mucosal biopsy specimen were taken from all 40 
patients. Ten healthy volunteers without nasal complaints or nasal abnonnalities on ENT 
examination and a negative skin prick test were biopsied once and tissue specimens used as 
controls. 
Nasal biopsies 
At the time of biopsy, all patients had nasal complaints, as confmlled by their DRCs. After 
randomization of the biopsy side, specimens of nasal mucosa were taken from the lower edge of 
the inferior turbinate, about 2 cm posterior to the front edge, using a Gerritsma forceps with a 
cup diameter of2.5 Imn (3). 
Local anesthesia was obtained by placing a cotton-wool carrier with 50 mg cocaine and one 
drop of adrenaline (l: 1000) under the inferior turbinate but without touching the biopsy site. The 
specimens were embedded in Tissue-Tek II a.C.T. compound and frozen immediately. 
Nasal brush cytology 
Contralateral to the biopsy side a nasal brush sanIple was taken from the middle nasal fossa 
using the Gynobrush (Medeco, Eindhoven, The Netherlands). This is a modification of the 
technique advocated by Pipkom (10). In our experience, this brush is less painful than the 
Rhinobrush (also Medeco). The brush was immediately placed in RPM!. Within 3 days cytospin 
preparations were made and cells were stained with Giemsa and toluidine blue. 
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STAINING PROCEDURES 
Eosinophils 
The monoclonal antibodies (mAb) BMKI3, EG2 and Giemsa (Table 3) were used togetiler with 
tile immuno-alkaline phosphatase, anti-alkaline phosphatase (AP AAP) method. BMKI3 is a 
mAb against major basic protein and is reported to stain 95-97% of all eosinophils (13). EG2 is 
a mAb against eosinophilic cationic protein and stains the activated eosinophils (22). 
Sections of nasal mucosa were cut 6 micrometer thickness 011 a cryostat (Jung Frigocut 
2800El20/40), transferred to poly-L-Iysine-coated microscope slides, dried and fixed in acetone 
for 10 min at 20 degrees C. They were next rinsed in phosphate-buffered saline (PBS, pH 7.2), 
placed in a half-automatic stainer (Sequenza, Shandon), incubated with 2% bovine senUll 
albumin in PBS for 10 min and incubated with nonnal rabbit serunl (CLB, Amsterdam, the 
Netherlands) for 10 min. Following tilis the slides were incubated with the mAb for 30 min at 20 
degrees C, rinsed in PBS and TRIS buffer (PH 8.0), and incubated for 30 min with a new 
fuchsin substrate (Chroma, Kongen, Gennany). Finally, sections were rinsed with distilled 
water, counterstained with Mayer's hematoxylin, and mounted in glycerin-gelatin. Control 
staining was perfonned by substitution with PBS and incubation with an irrelevant mAb of the 
same subclass. 
Antibody 
BMKI3 
EG2 
Anti-lgE 
B7 
G3 
Titer 
1:200 
1:40 
1:250 
1:100 
1:250 
Histochemical dyes 
Giemsa 
Toluidine blue 
Specificity 
MBP 
ECP 
IgE 
Chymase 
Tryptase 
Source 
Sanbio, Uden, NL 
Phannacia, Woerdcn, NL 
Central Laboratory of the Netherlands Red Cross Blood 
Transfusion Service, Amsterdam, NL 
Chemicon, Temecula, California, USA 
Chemicon, Temecula, California, USA 
Source 
Merck, Amsterdam, NL 
BDH, Dorset, UK 
Table 3. Monoclonal antibodies and histochemical dyes used to study mucosal biopsies in patients with NANIPER 
(VMR) and controls. (MBP: major basic protein, ECP: eosinophilic cationic protein) 
Mast cells 
Toluidine blue, an aniline dye, stains mast cells luetachromatically. Tissue sections were stained 
with toluidine blue at pH 0.5 for 5 min and counts were performed immediately (4). The mAbs 
anti-chymase (B7) and anti-tryptase (G3) are masl cell specific (6). To check our atopic 
screening, the biopsy material was also stained with anti-IgE, since atopic patients usually have 
a large number of IgE-positive cells present in biopsy sections (4). For staining with anti-lgE, 
G3 '!I1d B7 (Table 3) supersensitive AP was used (BioGenex AZOOOUM). This protocol 
followed the AP AAP protocol up to tile first PBS rinse. Sections were then incubated with 
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nonnal goat serum (CLB, Amsterdam, the Netherlands) for 10 min and then for 60 min with the 
mAb. The sections were rinsed with PBS for 5 min and successively linked with biotinylated 
anti-mouse serum for 30 min, rinsed with PBS for 5 min and labeled WiOl streptavidin-AP 
(ssAP) for 30 min. They were next rinsed in PBS for 5 min and TRIS buffer (PH 8.0) for 5 min 
and then incubated for 30 min with new fuchsin, after which the protocol again confonned to the 
AP AAP protocol. Furthemlore, for a general evaluation and control counting of eosinophiis, 
hematoxylin-eosin (HE) and Giemsa staining were perfomled. 
Double staining of mast cells was achieved by a 60 min. incubation with biotinylated anti-
chymase, linked with anti-biotine alkaline-phosphatase for 30 min. After a 60 min. incubation 
with anti-tryptase.1inking is perfonned for 30 min. with rabbit anti-mouse peroxidase and then a 
30 min. labeling is perfonned with peroxidase anti-peroxidase after which samples were 
incubated with fast blue and AEC substrate. Slides were mOWlted in glycerin. 
LIGHT MICROSCOPIC EVALUATION 
Stained cells were counted in two sections of each biopsy specimen. The epithelium and lamina 
propria were evaluated separately. The total surface area of a section and its main parts (i.e. the 
epithelium and lamina propria) were estimated with the use of the Kontron Image Analysis 
System Videoplan. The mlil1ber of cellslmm' was calculated for the epithelium and the lamina 
propria. 
STATISTICAL ANALYSIS 
The Mano-Whitney U-test was used to compare the differences in cell counts between the 
groups. A P value < 0.05 was considered to indicate a significant difference. 
RESULTS 
Biopsy specimens 
The sections of nasal mucosa had an average surface area of 1.5 nun2 and were generally of 
good quality. All but two biopsy specimens were evaluated. One exclusion w~s made because of 
artifact resulting from defrosting of the specimen and the other specimen was displaced. The 
mAb-AP AAP and tile mAb-ssAP stauting showed red cells against a blue counterstained 
background. After toluidine-blue staining, mast cells could easily be identified by their dark-
violet, metachromatic granules against a background of faintly stained tissue. 
25 
EosinophUs 
The nwnbers of Giemsa-positive, BMK 13-positive and EG2-positive cellslnuu2 are shown in 
Table 4. Virtually no eosinophils were present in the lamina propria and the epithelimn of both 
groups and any differences between the two groups were not statistically significant. 
Mast cells and other IgE-positive cells 
The nwubers of toluidine-blue-positive, G3-positive, B7-positive and anti-IgE positive 
cells/mm' are shown in table 4. The number of B7-positive cells tended to he higher than the 
nmnber of 03-positive cells in both patients and controls. Both tended to be higher than the 
nwnber of toluidine-blue-positive cells. There were no significant differences between the two 
groups as to ceH numbers in the epithelium and lamina propria for the various staining methods. 
Biopsy specimens from 2 of 40 patients showed substantial numbers of eosinophils, mast cells, 
and IgE-positive cells. 
Eosinophils Patients (n=40) Controls (n 10) P-value 
Median (range) Median (range) 
Epithelium 
BMKI3 0(0-281) 0(0-53) Not significant 
EG2 0(0-128) 0(0-0) Not significant 
Giemsa 0(0-209) 0(0-9) Not significant 
Lamina propria 
BMK\3 0(0-138) 0(0-6) Not significant 
EG2 0(0282) 0(0-0) Not significant 
Giemsa 0(0-124) 0(0-1) Not significant 
Mast cells and Patients (n=40) Controls (n 10) P-value 
IgE+ cells Median (range) Median (range) 
Epithelium 
Toluidine blue 0(0-138) 0(0-4) Not significant 
Anti-tryptase 0(0-282) 0(0-29) Not significant 
Anti·chymase 0(0-40) 0(0-3) Not significant 
Anti-IgE 0(0-480) 0(0-198) Not significant 
Lamina propria 
Toluidine blue 22 (0-101) 17 (9-51) Not significant 
Anti-tryptase 74 (1-162) 70 (9-96) Not significant 
Anti·chymase 75 (25-238) 54 (24-83) Not significant 
Anti-IgE 21 (0-338) 7 (0-152) Not significant 
Table 4. Medain and range ( - ) of numbers of eosinophils , mast cells and other IgE+ cells in the nasal mucosa of 
patients with NANIPER (VMR) and controls. 
Brush material 
A tolal of 500 cells were counted per cytospin. Toluidine-blue-positive cells were found in just 
one cytopsin (50 toluidine-blue-positive cells per 500 counted cells). Eosinophils were not 
found. 
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DISCUSSION 
We selected 155 patients with a history of nasal complaints for which no explanation could be 
found. However, only 40 of these patients satisfied our condition for inclusion in our study of 
nasal complaints for more than 1 h a day. That patients often overestimate nasal complaints 
underscores the importance of the use ofDRCs to characterize patients objectively. The duration 
of complaints was used as our prime criterion. It is also common knowledge that subjective 
complaint scores in which the intensity of the complaints are graded can be influenced by a 
patient's state of mind. On a bad day, patients suffer more. Moreover, it is easier for a patient to 
score the duration of the complaints than to grade intensity. Biopsies from two patients with 
NANIPER had substantial numbers of IgE-positive cells, mast cells, and eosinophils. As a 
consequence, we feel that these patients were indeed allergic in spite of their negative allergy 
tests. The data of these two patients were included since they satisfied our overall inclusion 
criteria. 
BRUSH CYTOLOGY 
NANIPER patients with prominent nasal eosinophilia of 20% or more are subcategorized as 
NARES patients. In general the NARES group comprises IO - 13% of the NANIPER patients 
(14). Contrary to expectations, none of our patients showed eosinophilia in cytospin preparations 
ofbrush samples. TIus might be explained by the eosinoplulic subgroup being more susceptible 
to therapy (20). The use of nasal corticosteroids has gained increasing acceptance by the general 
practitioner during the last decade. It is tims possible that most NARES patients are less 
symptomatic with llasal corticosteroid spray and are therefore not referred to the ENT surgeon 
for further care. TIlis hypothesis is supportcd by the flnding in our group of patients that 
congestion was the primary symptom. In NARES patients sneezing and clear rhinorrhea are the 
main symptoms. Moreover, although in the eosinophilic subgroup polyps are seen clinically in 
30% of cases, polyps were an exclusion criterion in our series. 
BIOPSY SPECIMEN 
Eosinophils 
Since virtually no eosinophils were fOtuld with Giemsa or BMK13, not to mention activated 
eosinophils (i.e., EG2-positive cells), in biopsy specimens from our patients and controls, we 
currently believe that thesc cells are not important in the pathogenesis of NANIPER, excluding 
NARES. 
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Maslcells 
Anti-tryptase is reported to stain all mast cells while some of these tryptase-positive cells are 
also positive for chymase (6). Contrary to our expectation, the number of chymase-positive cells 
were not lower than the munber oftryptase-positive cells in our present study. Additionally, in 
sections that were double-stained with anti-chymase anti-tryptase, single chymase-positive cells 
were found (figure 1: page 102). We think that this is the result of our fixation method. While 
other authors all use Carnoy's solution for mast cell fixation, we fixed our sections with acetone. 
We then found fixation with Carnoy's solution drastically reduced the numbers of chymase-
positive and toluidine-blue-positive cells, whereas the number oftryptase-positive cells was only 
slightly reduced. We therefore prefer acetone fixation. 
Apart from the two biopsies that were previously mentioned, virtually no mast cells were found 
in the nasal epithelium from controls and patients. As reported by Okuda et aJ. (17) the 
predominant metachromatic cell in the lamina propria of the nasal mucosa is the mast cell, the 
basophilic neutrophil that can also be stained with toluidine blue, is generally not present in the 
lamina propria of the nasal mucosa. This is in accordance with our fmdings. 
To our surprise we fmUld no evidence for mast cell involvement in NANIPER. In allergic 
rhinitis cross-linking of IgE on the membrane of the mast cells and the subsequent release of 
mast cell mediators (degranulation) is thought to contribute substantially to the complaints 
associated with rhinitis. We detected no specific IgE (by RAST and skin-prick test) and there 
was no significant difference in the number of IgE-positive cells between our NANIPER 
patients and the controls. Apart from the two biopsies with substantial numbers of eosinophils, 
mast cells and anti-IgE positive cells, np evidence for degranulation as a results of IgE cross-
linking was found. Separate studies have shown that neuropeptides have been found to induce 
degranulation in mast cells (2). Support for neuropeptide involvements in NANlPER has been 
foood by investigations demonstrating a reduction in nasal complaints associated with a 
depletion of sensory neuropeptides by prior treatment with capsaicin (21). A recent study by 
Lacroix's group (11) also fOlUId an increased concentration of sensory neuropeptides in the nasal 
mucosa of patients with chronic non-allergic rhinitis. 
One could hypothesize that an increased neuropeptide content could induce an ongoing 
degranulation of mast cells and thus a release of mast cell mediators, resulting in a possible 
decrease in mast cell numbers. However, a reduction in mast cell nWllbers was not found in our 
group of patients. Further evaluation of mast cell degranulation by electron microscopy in 
studies is in progress. In the near future we will report on the involvement ofT -cell subsets, and 
other inflarrunatory cells, including cytokine production. 
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Chapter 3 
Inflammatory Cells are not Involved in Non-Allergic Non-Infectious Perennial 
Rhinitis. 
H. M. Blom, A. KleinJan, P. O. H. Mulder, W. J. Fokkens, E. Rijntjes. 
Submitted for publication 
SUMMARY 
Mucosal inflammatory cell densities are correlated with nasal complaints in NANIPER. 
Some authors suggest inflammation of neurogenic or immunogenic nature as wlderlying 
disorder for NANIPER. We examined whether inflrulllilatory cells are involved in the 
pathogenesis ofNANIPER. Nasal biopsies were taken of sixty-five patients with significant 
nasal complaints and twenty controls without nasal complaints. Inflammatory cells were 
quantified, using monoclonal antibodies directed against lymphocytes, antigen presenting 
cells, eosinophils, mast ceiJs, macrophages and mOllocytes. No significant differences were 
found, for any cell, between patients and controls. \Ve conclude that inflammatory cells are 
not involved in NANIPER. 
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INTRODUCTION 
Non~allergic non-infectious perennial rhinitis, henceforth referred to as NANIPER, is a 
diagnosis by exclusion. This disorder probably represents a heterogeneous group of 
pathophysiological conditions. Proposed mechanisms include a chronic inflammatory 
disorder of antigenic or neurogenic nature, 
Neurogenic 
Wolf suggested that NANIPER could he the result of an ttover-active" non-adrenergic non-
cholinergic system (1), Stimulation of sensory neurons results in sensory nasal changes, 
rhinorrhea (2), nasal blockage and sneezing. Sensory neural stimulation may produce these 
effects either through a central neural reflex, associated with efferent parasympathetic 
neurotransmission, or via anti-dromic release of lleuropeptides from sensory neurons (3). 
Tllis hypothesis was corroborated by the findings of Lacroix who reported an increased 
concentration of neuropeptides in a group of chronic non-allergic rhinitis patients (4). 
improvement of symptoms by local treatment of capsaicin giving a 50% reduction in CGRP-
Ii content in nasal biopsies (5). and a correlation between symptoms intensity and CGRP-Li 
concentration in nasal mucosa (6). 
An increase of proinflammatory neuropeptides could result in a stimulation of T-cell 
proliferation. stimulation of mast celis, macrophages and eosinophils. and chemoattraction of 
eosillopllils and neutropllils (7). Substance P is able to increase the percentage of neutrophils 
recovered from nasal lavage (8). Capsaicin. a specific activator of sensory nerve endings. 
induces a neurogenic inflammation. with an influx of inflammatory cells in nasal lavage after 
a single provocation (9). In 1990, Moneret- Vautrin (10) suggested that non-allergic rhinitis 
with eosinophilia syndrome (NARES), a subgroup of vasomotor rhinitis (II), originates as a 
neurogenic inflammation. 
Antigenic 
Another theory conceming the pathogenesis of NANIPER is that of a local, occult allergy 
(12). The diagnosis ofNANIPER is made by exclusion. An allergy test is not 100% sensitive 
and systemic manifestations, such as a positive skin prick test or RAST,. of atopic disease 
might be missed because the nose is a small shock organ. In seasonal or perennial allergic 
rhinitis increased numbers of inflammatory cells, such as e.g. Langerhans cells, IgE positive 
cells, and eosinophils, can be found in the nasal mucosa as a sign of inflammation (13-15). 
In order to determine whether there is an increase of inflammatory cells in the nasal mucosa 
of NANIPER patients we performed a nasal biopsy study in 65 NANIPER patients and 20 
healthy controls. 
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MATERIALS AND METHODS 
Patients and controls 
The selection of patients has been described before (20). In short the 65 patients (male/female 
32/33); mean age of34 years (17-62 years), 20 non-smokers, 16 ex-smokers (had not smoked 
for more than I year) and 29 current smokers, 1 Oriental, 56 Caucasian, 6 Asian, and 1 
African. They all had negative skin prick test and RAST. All patients had complaints of nasal 
obstruction, and/or rhinorrhea and/or sneezing for more than 1 hour per day for at least 5 days 
during a period of 14 days. 
The controls consisting of twenty healthy volunteers (male/female 1119); mean age 36 years 
(18-62), 9 nOll-smokers, 2 ex-smokers, 9 current smokers, 16 Caucasian, 3 Oriental, and 1 
Asian, without nasal complaints or nasal abnormalities on ENT-examination, a negative skin 
prick test for the common inhalation allergens (l6) and a negative Phadiatop (phannacia, 
Uppsala, Sweden). Patients and controls were biopsied once. Procedures were approved by 
the local Medical Ethics committees. 
Nasal biopsies 
At the time of the biopsy, all patients had nasal complaints, as confinned by their daily record 
charts. After randomization of the biopsy side, specimen of nasal mucosa were taken from the 
lower edge of the inferior turbinate, about 2 cm posterior to the front edge, using a Gerritsma 
forceps with a cup diameter of 2.5 mm. (17). Local anesthesia was obtained by placing a 
cotton-wool carrier with 50 mg of cocaine and one drop of adrenaline (I: I 000) under the 
inferior turbinate without touching the biopsy site. The specimen were embedded in Tissue-
Tek II a.C.T. compound and frozen immediately. 
Staining procedures 
Monoclonal antibodies (mAb) directed against CD I, cm, CD4, CD8, CD 14, CD68, CD25, 
chymase, tryptase, IgE, and BMK13 (table I) were used together with the super sensitive 
on a cryostat (Jung Frigocut 2800E/20/40), transferred to poly-L-Iysine-coated microscope 
slides, dried, and fixed in acetone for 10 min at room temperature (RT). They were then 
rinsed in phosphate-buffered saline (PBS, pH 7.2), placed in a half-automatic stainer 
(Sequenza, Shandon), incubated with 2 % bovine semm albumin in PBS for 10 min and 
incubated with nonnal goat serum (CLB, Amsterdam, The Netherlands) for 10 min. 
Following this the slides were incubated with the mAb for 30 min at RT. 
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Antibody Specificity 
CDI OKT6 
CD3 leu4 
CD4 leu3 
CD8 leu2 
CD25 IL2-r 
B7 Chymase 
OJ Tryptase 
BMKI3 MBP 
CDI4 monll 
anli-IgE IgE 
CD68 KI-M6 
Titer 
1:100 
1:25 
1:50 
1:100 
1:150 
1:100 
1:250 
1:200 
1:20 
1:250 
1:50 
Source 
Dept. Immunology, Erasmus University, Rotterdam, 
The Netherlands (NL) 
BDH, Dorset, UK 
Chemicon, Temecula, Calif, USA 
Sanbio, Uden, NL 
Central labaratory of the Netherlands Red Cross Blood 
Transfusion service (CLB), Amsterdam, NL 
Behring, Marburg, Germany 
Table l. Monoclonal antibodies used to study mucosal biopsies in patients with NANIPER and controls. 
The sections were then rinsed again in PBS for 5 min and incubated for 30 min with a 
biotinylated goat anti-mouse (l :50) immunoglobulin antisemm, rinsed successively in PBS, 
incubated with strept Avidin AP (1:50) (Biogenics, Klinipath, Duiven, The Netherlands) for 
30 min at RT, rinsed in PBS and TRIS buffer (PH 8,0), and incubated for 30 min with a new 
fuchsin substrate (Chroma, Kongen, Gennany), Finally, sections were rinsed with distilled 
water, counterstained with Gills hematoxylin and mounted in glycerin-gelatin. Control 
staining was performed by substitution with PBS and incubation with an irrelevant mAb of 
the same subclass. 
Light-microscopic evaluation 
Stained cells were counted in two sections of each biopsy specimen. The epitheHum and 
lamina propria were evaluated separately. The total surface area of a section and its main 
parts (i.e. the epithelium and the lamina propria) were estimated with the use of the Kontron 
Image Analysis System Videoplan, The number of cells/mm' was calculated for the 
epithelium and the lamina propria, 
Statistical analysis. 
The non-parametric Mallll-\Vhitney U-test was used to compare the differences in cell counts 
between the groups, A p-value < 0,05 was considered to indicate a significant difference. 
The mean difference between patients and controls is considered significant if it exceeds 
twice its standard error, To determine whether the groups in this study were large enough to 
validate our conclusions (to avoid a type 2 statistical error), The standard error of the mean 
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difference after Ln-transfonnation of the cell counts was detennined in order to compensate 
for the skewness of the cell counts to justifY parametric testing. The antilog of twice this 
difference gives the smallest ratio between the geometric means (estimation of the median if 
the variables have a normal distribution after Ln transfonnation ) of both groups that would 
be significant at the 5% level in our study. For instance, if the geometric mean of the control 
group were 10 and the calculated ratio 2.6, the geometric mean of the patient group must 
exceed 26 in order to reach significance in the measurements. All analysis were perfonned 011 
a personal computer using statistical software (SPSS 6.0.1 for Windows). 
RESULTS 
Biopsy specimen 
The sections of the nasal mucosa had an average surface area of 1.6 nm12 and usually showed 
a lining of ciliated columnar epithelium with or without goblet cells and/ or partially stratified 
cuboidal epithelium. The lamina propria consisted usually of a looser subepithelial cell-rich 
layer with most of the mucous glands and a deeper collagenous cell-poor layer. All sections 
were sufficiently deep to assess both layers. The sections were generally of good qUality. 
Two biopsy specimen could not be evaluated (18). The mAb-ss-AP staining showed red cells 
against a blue counterstained background. Biopsy specimens from 2 of the 65 patients 
showed substantial numbers of eosinophils, langerhans cells, mast cells and IgE-positive 
cells. 
T-Iymphocyfes 
These small round cells were abundantly present in the epithelium as well as in the lamina 
propria. Sometimes, clusters of T-cells (500-1000 cells) were found in the lamina propria. 
The occurrence of these clusters did not differ between the groups. 
The number of CD3, CD4 (figure 6, page 107: G, H), CD8 (figure 6, page 107: E, F), and 
CD25 positive cells/nun' are shown in table 2. As can be seen, hardly any IL-2 receptor 
(CD25) positive cells were found in either layer of the nasal mucosa. If there were any 
differences between the two groups at all, tlley were not statistically significant. The 
calculated ratios indicating threshold significance for the groups were respectively: CD3 
epithelium (EP) 1.57, CD3 lamina propria (LP) 1.47, CD4 EP 1.78, CD4 LP 1.5, CD8 EP 
1.88, CD8 LP 1.73, CD25 EP 2.63, CD25 LP 2,38. 
Lallgerhalls cells 
This large dendritic cell was found mostly in the epithelium. Only a few were present in the 
lamina propria. The numbers of CD I-positive cells are shown in table 2. No significant 
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differences were found. The calculated ratios indicating threshold significance for the groups 
were: CD 1 EP 1'.86, CD! LP 2.20 
Cell type Controls Patients p~value 
Median(25 %-75%) Median(25%-75%) 
Ep(thelium 
COl 48(15-130) 54(15-110) 0.82 
CD3 512(299-867) 630(347-1079) 0.27 
CD4 545(341-755) 424(223-584) 0.18 
CD8 305(173·431) 446(163-762) 0.11 
CDI4 310(130·497) 215(179-316) 0.68 
CD25 8(0-30) 0(0-25) 0.43 
BMKI3 0(0·0) 0(0-0) 0.60 
Tryptase 0(0-4) 0(0·4) 0.88 
Chymase 0(0-0) 0(0-8) 0.06 
IgE 0(0-0) 0(0-28) 0.30 
CD68 165(89-293) 214(136·378) 0.06 
Lamina propria 
COl 3(1-8) 5(1-13) 0.54 
CD3 678(486-832) 552(300·872) 0.31 
CD4 464(181-885) 426(259-611) 0.65 
CD8 269(160-345) 295(147-476) 0.51 
CDI4 232(143-367) 196(161-271) 0.58 
CD25 7(2-58) 3(0-13) 0.30 
BMKI3 0(0·0) 0(0-3) 0.18 
Tryptase 65(41-71) 69(38-97) 0.30 
Chymase 54(47-71) 63(46-100) 0.35 
IgE 8(2-62) 22(4-64) 0.67 
CD68 145(74-195) 152(101-250) 0.30 
Table 2. Median (25th and 75th percentile) of positive cellslnlln2 in epithelium and lamina propria of the nasal 
mucosa. 
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Macrophages and monocyfes 
The CD68 positive cells were large cells with a bright staining cytoplasm. These cells were 
found to be equally distributed in both layers, as was CD 14. The number of CD68 and CD 14 
cells are shown in table 2. No significant differences were found. The calculated differences 
indicating threshold significance for the groups were: CDI4 EP 1.68, CDI4 LP 1.55, CD68 
EP 1.44, CD 68 LP 1.52. 
Mast ce/ls and other JgE-positive cells 
The chymase and tryptase and IgE positive cells (figure 6, page 106: C, D) were found 
mainly in the lamina propria. The numbers are shown in table 2. No significant differences 
were fOlUld. The calculated differences indicating threshold significance for the groups were: 
anti-IgE EP 4.22, anti-IgE LP 3.17, tryptase EP 2.62, tryptase LP 1.57, chymase EP 2.47, 
chymase LP 1.61. 
Eosinophils 
The number ofBMK13 positive cells found in the nasal mucosa of both patients and controls 
were negligible (figure 6: page 106: A, B). No significant differences were found. The 
nwnbers are shown in table 2. The calculated differences indicating threshold significance for 
the groups were: BMKI3 EP 1.96, BMKI3 LP 2.21. 
DISCUSSION 
NANIPER is an intriguing disorder. By strict selection and by using a complaint threshold 
value, we succeeded in achieving a homogenous group of patients. As NANIPER is reported 
to account for between 30% and 70% of cases of chronic perennial rhinitis (19), we were 
surprised to find that only sixty-five out of the 300 selected patients satisfied our inclusion 
criterions such as nasal complaints for more than th/day. Tilis, once again, lmderlines the 
importance of the use of nasal symptom scores to characterize the patients objectively (18, 
20). The 2 patients, of the total of 65 with negative allergy tests, with a snbstantial typical 
cellular allergic infiltrate in the nasal mucosa were classified as possible sufferers of an occult 
local allergy. This would mean a maximum prevalence of three percent of occult allergy in 
this group that can be discemed by nasal biopsies. In this NANIPER group no signs of 
inflammation were found. This contrasts with the findings of Lacroix (4). However, his 
patients, underwent either functional sinus surgery or were suffering from a drug-induced 
rhinitis and so probably cannot be characterized as typical NANIPER patients. Moreover, the 
reported increase of inflammatory cells in his biopsies could well be the result of infection. 
The presented data is in accordance with recent data by Sanieo who was unable to find an 
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increased responsiveness to capsaicin in a group of 8 non-allergic rhinitis patients. He 
therefore discarded a central role for capsaicin sensitive nerves (pivotal in the concept of 
neurogenic inflammation) in the pathophysiology ofNANIPER (22). The question then arises 
as to whether this immunohistochemical evaluation method is sensitive enough to detect 
significant differences between the groups. The calculated ratios between the geometric 
means of both groups indicating threshold significance at the 5% level are within the range 
found in patients with chronic allergic rhinitis (13-15). In these studies, which compare 
symptomatic allergic patients with asymptomatic controls, cellular differences between 
patients and controls were indeed found, while the distribution of the number of 
immunocompetent cells/mnl was in the same order of magnitude as in this NANIPER study. 
We therefore think it is justified to assume that if significant mucosal inflatmnation would be 
present, we would have detected it. The lack of differences in cell numbers does not exclude 
a functional cellular involvement. However, in two recent studies we failed to ascertain a 
relation between the number of immunocompetent cells and nasal complaints in NANIPER 
patients (20,21). A significant reduction of inununocompetent cells in the nasal mucosa of 
NANIPER patients treated with nasal steroids (fluticasone aqueous nasal spray) was not 
accompanied by a reduction in nasal complaints (20) and ,vice versa, a significant reduction 
in nasal complaints in a group of NANIPER patients treated with topical capsaicin aqueous 
nasal spray was not accompanied by a change in inflanunatory mediators (21) or a reduction 
in the numbers of inflanunatory cells. 
Considering the aforementioned we conclude that inflammatory cells are not involved in 
NANIPER. 
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Chapter 4 
The Effect of Nasal Steroid Aqueous Spray on Nasal Complaint Scores and 
Cellular Infiltrates in the Nasal Mucosa of Patients with a 
Non-Allergic Non-Infectious Perennial Rhinitis. 
H. M. Blom, T. Godthelp, W. J. Fokkens, A. KleinJan, P. G. H. Mulder, E. Rijntjes. 
Journal of Allergy and Clinicallmmnnology 1997;100:739-747 
SUMMARY 
The efficacy of topical steroids on nasal complaints and the effect on mucosal cell densities 
was studied in a group of 65 NANIPER patients. Topical corticosteroids are the therapy of 
choice in non-allergic non-infectious perennial rhinitis (NANIPER). However, the efficacy of 
the steroid therapy in NANIPER is controversial, as is its mode of action. To our surprise, out 
of 300 patients initially diagnosed as suffering from NANIPER, only 65 patients with 
NANIPER reached threshold nasal symptom scores. Patients were randomized into four 
different treatment regimes. Placebo bi daily (BD) for 8 weeks, Iluticasone 200 mg once daily 
(OD) and placebo OD for 8 weeks, Iluticasone 200 mg OD and placebo OD for 4 weeks 
followed by Iluticasone 200 mg BD for 4 weeks, and Iluticasone 200 mg (BD) for 8 weeks. A 
small decrease in nasal symptomatology was found which only reached significance for 
sneezing. A significant dose dependent decrease in immunocompetent cells was found in 
nasal biopsies obtained after 4 weeks, and after 8 weeks of treatment. We conclude that 
topical corticosteroids do not significantly improve nasal symptoms in this group of selected 
NANIPER patients, even though a significant effect was seen on cells in the nasal mucosa. 
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INTRODUCTION 
Topical corticosteriods became firmly established as the therapy of choice in the treatment of 
allergic rhinitis in the last decades. Patients suffering ITom this disorder do greatly benefit by 
this treatment (1,2). The effects of local steroids in the nasal mucosa in allergic rhinitis has 
been well documented (3-5). The first studies showing efficacy of topical steroids in 
NANIPER were performed in the late seventies and in the beginning of the eighties (6-8). 
Recent studies using fluticasone propionate aqueous nasal spray for the treatment of 
NANIPER have shown an efficacy comparable to the efficacy of topical steroids in allergic 
rhinitis (9). Philips in 1995 stated, however, that although some clinical efficacy has been 
demonstrated in non-allergic non-infectious perclll1ial rhinitis (NANIPER), these agents often 
do not provide the same relief as they do in allergic rhinitis (10). The etiology ofNANIPER 
has been attributed to, basically, 2 theories (ll). The first theory assumes an imbalance 
between adrcncrge and cholinerge itmcrvation of the nasal mucosa (12). In this scenario, 
underactivity of the sympathetic nervous system leads to nasal obstruction; whereas 
overactivity of the parasympathetic nervous system leads to rhinorrhoea (13). Support for this 
theory was found by \Vilde in 1996 who showed an abnonnal response to isometric exercise 
in NANIPER, possible due to relative nasal sympathetic hyposensitivity (14). 
According to the second theory, NANIPER, could be the result of an !tover-active" non-
adrenergic non-cholinergic (NANC) system, resulting in a neurogenic inflanm13tion (15, 16). 
Stimulation of sensory neurons results in sensory Hasal changes, rhinorrhoea (17), nasal 
blockage and sneezing. Sensory neural stimulation may produce these effects either through a 
central neural reflex, associated with efferent parasympathetic neurotransmission, or via anti-
dromic release of neufOpeptides from sensory neurons (18). To support this hypothesis, 
Lacroix reported an increased concentration of neuropeptides in a group of chronic rhinitis 
patients (19). A theoretical basis, in line with the second theory, for the efficacy of steroid 
therapy was found when steroids were reported to upregulate neutral endo peptidase. which 
degrades neuropeptides (20) and inhibit neurogenic plasma extravasation (21). 
By its nature as a diagnosis made by exclusion, NANIPER probably represents a 
heterogeneous group of pathophysiological conditions. To study this disorder (in a second 
echelon setting) we applied strict selection criteria. We excluded patients with systemic, 
medical and anatomical disorders that could explain complaints of rhinorrhoea, sneezing, and 
nasal obstruction. This remaining group was further homogenized on the basis of a daily 
record chart On which patients had to reach a minimum symptom score. 
Using modem immunohistochemical staining methods, no data are available on the effect of 
local corticosteroid therapy on cellular infiltrates in the nasal mucosa in NANIPER patients. 
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We studied the effect of different treatment regimes in NANIPER on nasal complaints and 
cellular infiltrates. 
MATERIALS AND METHODS 
Patients were studied from 1988 to 1993 in the outpatient ENT departments of the Leyenburg 
Hospital in the Hague and the Dijkzigt University Hospital in Rotterdam, The Netherlands. 
Patients were admitted to the study if they had a history of nasal complaints such as nasal 
obstruction, sneezing, and rhinorrhea for a period of over 1 year which could not be attributed 
to allergic rhinitis, nasal or paranasal sinus infection, anatomical disorders affecting nasal 
function, pregnancy or lactation, systemic disorders and/or the use of medication affecting 
nasal function (table I). Patients with nasal polyps were excluded, since they may belong to a 
different pathophysiological group and their polyps may contribute to a higher symptom 
score for nasal blockage andlor rhinorrhea. Three-hundred patients, with the diagnosis of 
NANIPER, scored the duration of their nasal complaints, twice daily, for a period of2 weeks 
using a daily record chart (DRe) (fig I). 
Possible scores on the daily record chart 
Nasal blockage: 
(not being able to breathe freely through the nose) 
Clear nasal discharge: (runny nose) 
Sneezing 
Coughing 
Mucus production: 
(yellow, green or brown) 
o absent 
I = between 0-) h per half day 
2 = between 1-2 h per half day 
3 = more than 2 h per half day 
0= absent 
J = less than 5 periods per half day 
2 = between 5~ I 0 periods per half day 
3 = more than 10 periods per half day 
O=absent 
I = present 
Figure I. Scheme of the daily record card for defining nasal symptoms in patients with NANIPER (VMR). 
In affected patients periods of nasal discharge, sneezing and congestion had to persist for an 
average of at least Ih per day for at least 5 days during a period of 14 days. The duration of 
complaints during the day was used as the prime criterion for further study. At every visit the 
subjects also rated the intensity of their nasal symptoms during the last three days on a visual 
analogue scale (V AS) (0-10 cm, 0 represented absence of symptoms and 10 represented 
severe intensity of symptoms). Sixty-five of the 300 patients were found eligible for our 
study and participated under conditions of informed consent (male/female: 32/33); mean age 
was 34 years (17-62y). Twenty patients had never smoked, 16 were ex-smokers (had not 
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smoked for more than 1 year), 29 were current smokers. Ethnic origin of the patients: 
Oriental 1, Caucasian 56, Negroid 2, Asian 6. 
Inelusion criteria 
- Age between 16 and 64 years. 
- Negative skin prick test: house dust mite, tree pollen mix, grass pollen mix, bijvoet, alternaria, 
aspergillus, cladosporium, penicillum, dog, cat, parakeet, rabbit, hamster, horse, guinea pig. (ALK-
Diephuis, Holland) 
- Negative Phadiatop (Phamlacia, Uppsala, Sweden) 
- Symptoms for more than I year. 
- Periods of nasal discharge, sneezing and congestion for an average of at least I h per day for at least 
5 days during a period of 14 days. 
Exc/usioll criteria 
- The use of systemic or inhaled corticosteroids within the previous month. 
- Use of inhaled sodium cromoglycate or nedocromil sodium within the previous month. 
- Use of astemizole within the previous month. 
- Inability oflhe patient to stop taking medication affecting nasal function. 
- A serious and/or unstable disease. 
- Nasal surgery within the previous 6 weeks. 
- Nasal polyps or a history of nasal polyps. 
- Significant anatomical abnonnalities affecting nasal function. 
- Nasal or paranasal sinus infection (abnomlal sinus X-ray). 
- Pregnancy or lactation 
- Abnomlal findings at physical examination. 
- Abnomlallaboratory results for: 
blood: Na, K, Ca, total protein, albumin, urea, creatinine, bilimbin, alkaline phosphatase, aspartate 
aminotransferase, alanine aminotransferase, gammaglutamyl transpeptidase, hemoglobin, red blood cell 
count, plasma cell volume, mean corpuscular volume, platelets, total white blood cellcount, 
neutrophils, lymphocytes, monocytes, eosinophils, basophils. 
urine: blood, protein, glucose. 
Table I. Selection criteria for non-allergic non-infectious rhinitis. 
Study design 
A single investigator, multi-center double blind, placebo controlled study. All patients started 
with a run-in period of 2 weeks in which they received placebo aqueous spray and recorded 
their nasal complaints. Eligible patients were randomized into one of the four different 
treatment regimes; placebo bi daily (BD) for 8 weeks, fluticasone 200 mg once daily (OD) 
and placebo OD for 8 weeks, fluticasone 200 mg OD and placebo OD for 4 weeks followed 
by fluticasone 200 mg BD for 4 weeks, and fluticasone 200 mg (BD) for 8 weeks (Fig 2). The 
. treatment period was divided in 2 periods of 4 weeks. Terfenadine tablets (60mg) were used 
as rescue medication. The study protocol was approved by the ethical review committees, and 
conducted in accordance with the declaration of Helsinki. 
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visit 1 visit 2 visit 3 visit 4 
H2"""ks I 14 weeks I 14 weeks I 
n = 16 n = 16 n = 16 
ftuticasone 200 fluticasone 200 I 
0=15 I fluticasone 400 I n= 15 fluticasone 400 I I 
0=65 
n = 18 n = 18 n = 18 
fluticasone 200 fluticasone 400 I 
n = 16 ~ n= 16 I I 
biopsy 1 biopsy 2 biopsy 3 
VAS ORC VAS ORC VAS ORe VAS 
I I I I 
Figure 2. Study design. 200 = FPANS 200 Jlg once daily, 400 = FPANS 200 Jig hi-daily, VAS = visual analogue 
scale, DRC = daily record chart 
Sympfomscores 
For each of the symptoms of nasal blockage on waking. and nasal blockage during the rest of 
the day, sneezing on waking and during the rest of the day, and rhinorrhoea on waking and 
during the rest of the day, the scores were summarized separately by the percentage of 
symptom-free days as was done by Scadding (9). 
The mean sumscore for blockage, sneezing, and congestion was calculated during the week 
previous to visit 2, the week previous to visit 3, and the week previous to visit 4, since the 
effect of fluticasone on nasal symptoms in our clinical experience reaches a steady state 1 to 
2 weeks after the start of treatment. In order to moderate the fluctuations in DRC scores per 
patient the mean sumscore of one week was used. 
The mean scores for coughing; mucus production; eye irritation; and the number of 
terfenadine tablets used were recorded. 
The V AS was scored each visit, during which the patient was asked to rate the intensity of 
nasal symptoms during the last 3 days. This was pragmatically considered to be the golden 
mean between moderating the extremes in nasal symptoms per patient by using several days, 
and having a reasonable reliable recollection period for the patients' nasal symptoms by 
taking only 3 days. At each clinic visit the investigator scored the patients' symptoms of nasal 
blockage, sneezing, rhinorrhoea and post-nasal drip on a severity scale of 0-3 (O~ no 
symptoms; 1 = mild; 2 = moderate; 3 = severe). The nose was assessed by rhinoscopy. 
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Turbinate swelling; crusting; bleeding; colour of the mucosa; and secretions were noted as 
nonnal or abnonnal. 
Safety was assessed by monitoring adverse events at each clinic visit. Biochemistry, 
hematology and urinalysis were evaluated at baseline and at the end of treatment. 
Nasal biopsies. 
Nasal biopsies were perfonned after the run-in period, after 4 weeks of treatment and after 8 
weeks of treatment in each patient (fig,2). After randomization of the biopsy side, specimen 
of nasal mucosa were taken from the lower edge of the inferior turbinate, about 2 cm 
posterior to the front edge, using a Gerritsma forceps with a cup diameter of 2.5 mm (22). 
Local anaesthesia was obtained by placing a cotton-wool carrier with 50 mg of cocaine and 
one drop of adrenaline (1:1000) under the inferior turbinate without touching the biopsy site. 
The specimen were embedded in Tissue-Tek II O.C.T. compound and frozen immediately. 
Nasal brush cytology 
Contralateral to the biopsy side a nasal brush sample was taken, after the run-in period, from 
the middle nasal fossa using the Gynobrush (Medeco, Eindhoven, The Netherlands). The 
brush was immediately placed in RPMI. \Vithin 3 days cytospin preparations were made and 
cells were stained with Giemsa and toluidine blue (23). 
Staining procedures 
Monoclonal antibodies (mAb) directed against CDt, CD3, CD4, CD8, CD25, IgE, MBP, 
Chymase, and Tryptase (table 2) were used together with the super sensitive immuno-alkaline 
phosphatase (ss-AP) method. Sections of nasal mucosa were cut in 6 
Frigocut 2800E/20/40), transferred to poly-L-lysine-coated microscope slides, dried, and 
fixed in acetone for 10 min at room temperature (R T). They were next rinsed in phosphate-
buffered saline (PBS, pH 7.6), placed in a half-automatic stainer (Sequenza, Shandon), 
incubated with 2 % bovine senun albumin in PBS for 10 min and incubated with normal 
goatserum (CLB, Amsterdam, The Netherlands) for 10 min. Following this the slides were 
incubated with the mAb for 60 min at RT. The sections were then rinsed again in PBS for 5 
min and incubated for 30 min with a biotinylated goat anti-mouse (l :50) immunoglobulin 
antiserum, rinsed successively in PBS, incubated with strept Avidin AP (1:50) (Biogenics, 
K1inipath, Duiven, The Netherlands) for 30 min at RT, rinsed in PBS and TRlS buffer (PH 
8.5), and incubated for 30 min with a new fuchsin substrate (Chroma, Kongen, Germany). 
Finally, sections were rinsed with distilled water, counterstained with Gills hematoxylin and 
mounted in glycerin-gelatin. Control staining was performed by substitution with PBS and 
incubation with an irrelevant mAb of the same subclass. Toluidine blue, an analine dye, 
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stains mast cells metachromatically. The cytospin preparations were stained with toluidine 
blue at pH 0.5 for 5 min and COUlltS were performed immediately (24). Separate cytospin 
preparations were stained with May Grunwald-Giemsa (MGG) to study eosinophils. 
Antibody 
OKT6 
leu4 
leu3 
leu2 
IL-2r 
BMKI3 
B7 
G3 
Specificity 
CD! 
cm 
CD4 
CDS 
IgE 
C025 
MBP 
Chymase 
Tryptase 
Titer Source 
1:100 Dept. Immunology, Erasmus University, Rotterdam 
1:25 BD, Dorset, UK 
1:50 BD, Dorset, UK 
1:100 BD, Dorset, UK 
1:250 Central laboratory of the Netherlands Red Cross Blood 
Transfusion service (CLB), Amsterdam, NL 
1:150 BO, Dorset, UK 
1:200 Sanbio, Uden, The Netherlands 
1:100 Chemicon, Temecula, Calif, USA 
1:250 Chemicon, Temecula, Calif, USA 
Table 2. Monoclonal antibodies used to study nasal mucosal biopsies of patients and controls. 
Light-microscopic evaluation 
Stained cells were cotU1ted in two sections of each biopsy specimen. The epithelium and 
lamina propria were evaluated separately. The total surface area of a section and its main 
parts (Le. the epithelium and the lamina propria) were estimated with the use of the Kontron 
Image Analysis System Videoplan. The number of cells/mm' was calculated for Ihe 
epithelium and the lamina propria. 
Statistics 
Statistical analysis of symptomatology was carried out using differences from baseline 
(Kruskal-Wallis .I-way anova). 
Assessment by the investigator was analyzed using Mantel-Haenszel test for linear 
association. 
The biopsy data of the flulicasolle 200 OD and the lJuticasone 200 OBD was pooled for 
biopsy number 2 since these groups received the same treatment up to that moment. The 
Mann-Whitney U-test was used to compare the differences in cell counts between the groups. 
A P value < 0.05 was considered to indicate a significant difference. 
We calculated the Speerrnan rank correlations between changes in cell numbers and the 
changes in the V AS scores per randomization group. 
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RESULTS 
Symptom scores 
Figure 3 shows the changes in the percentage of symptom free days during the treatment 
compared with baseline. A small decrease in symptomatology was found, which only reached 
significance for sneezing. The mean increase in the percentage of symptom free days for 
sneezing in the FP 3D was significantly better than in the placebo group comparing baseline 
and 8 weeks of treatment. (28 increase in percent points for FP BD vs 5 percent decrease in 
percent points for placebo), No significant difference between the four treatment groups was 
seen for coughing; mucus production; eye irritation; and the number of terfenadine tablets 
used. No significant changes were seen for the mean sumscores (fig. 4) (l week before each 
visit) and the VAS score (fig. 5) between the four treatment groups. There were no 
statistically significant differences between the four treatment regimes in the investigators's 
assessment of symptoms and rhinoscopy at Clinic visits. Vle found no correlation larger than 
0.7 absolutely which approximately coincides with testing at alpha ~ 0.01 between cell 
counts and nasal symptoms, given the size of the randomization groups. 
No major adverse events occurred and there were no relevant changes in the routine 
biochemical, and hematological tests and urinalysis. 
Nasal brushes 
A total of 500 cells were counted per cytospin. Toluidin blue-positive cells were found in just 
one cytospin (50 toluidine-blue positive cells per 500). Eosinophils were not found in 
cytospins stained with MOO. 
Biopsy specimens 
The sections of the nasal mucosa had an average surface area of J.6 nun2 and usually showed 
a lining of ciliated columnar epithelium with or without goblet cells and! or partially stratified 
cuboidal epithelium. The lamina propria consisted usually of a looser subepithelial cell-rich 
layer with most of the mucous glands and a deeper collagenous cell-poor layer. All sections 
were sufficiently deep to assess both layers. The sections were generally of good quality. 
Two biopsy specimen could not be evaluated, one got -defrosted, and one was'misplaced. The 
mAb-ss AP staining showed red cells against a blue counterstained background. T-
lymfocytes, small round celis, were abundantly present in the epithelium as well as the 
lamina propria. Sometimes clusters of T-cells were found in epithelium or lamina propria. 
The occurrence of these clusters did not differ between the groups. Langerhans cells, large 
dendritic cells, were found mostly in the epithelium. Only a few were present in the lamina 
propria. Mast cells were found mostly in the lamina propria and hardly in the epithelium. 
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Eosinophils were hardly present in our material. Sometimes moderate infiltrates were found 
in the mucosa. The occurrence did not differ between the groups in the first biopsies. 
Median cell numbers and 25 percentile and 75 percentile are shown for CDl, CD3, CD4, 
CDS, CD25, IgE, MBP, Tryptase, and chymase positive cells in the epithelium and lamina 
p'ropria in tabel 3 a and b. Table 4 (after 4 weeks of treatment) and 5 (after 8 weeks of 
treatment) show the results after statistical evaluation for the different biopsy moments and 
treatment regimes. 
No significant difference was found between the different groups before treatment (biopsy 
number 1), A marked effect was seen on the number of Langerhans cells and T -cells. The 
effect of the double steroid dose was more marked than that of the single dose. No additional 
effect of 4 consecutive weeks of steroid treatment was found after the first 4 weeks of 
treatment in the epithelium. In the lamina propria 4 extra weeks of treatment seems to effect 
the mast cells and eosinophils if present. 
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EPITHELIUM run in 4 weeks 8 weeks 
median 25%-75% median 25%·75% median 25%-75% 
COl placebo 55 22-134 23 0-122 50 27-126 
200 52 4-150 0 0-3 3 0-17 
200/400 83 35-110 0 0-16 0 0-3 
400 50 8-129 0 0-0 0 0-0 
CD3 placebo 936 423-1143 488 250-848 347 215-656 
200 623 471-800 115 60-477 145 50-463 
200/400 652 331-1208 192 71-383 65 14-114 
400 403 257-789 151 38-348 210 10-317 
CD4 placebo 386 190-544 255 104-514 187 86-331 
200 486 327-1192 63 14-162 78 10-167 
200/400 453 277-674 195 43-343 30 11--76 
400 336 184-716 20 6--93 33 13-98 
CD8 placebo 518 288-1018 224 129-629 92 37-241 
200 531 156-997 135 102-335 128 57-145 
200/400 448 127-663 141 73-228 24 9--80 
400 310 133-680 69 14-206 24 7-103 
CD25 placebo 20 2-39 15 6--38 20 5--34 
200 0 0-20 4 . 0-36 4 0-13 
200/400 8,5 0-24 O· 0-59 7 0-32 
400 0 0-18 0 0-20 4 0-27 
BMK 13 placebo 0 0-7 0 0-5 0 0-10 
200 0 0-8 0 0-0 0 0-0 
200/400 0 0-0 0 0-0 0 0-0 
400 0 0-1 0 0-0 0 0-0 
Tryptase placebo 0 0-20 0 0-0 0 0-2 
200 0 0-0 0 0-0 0 0-0 
200/400 0 0-12 0 0-0 0 0-0 
400 0 0-3 0 0-0 0 0-0 
Chymase placebo 0 0-10 0 0-0 0 0-0 
200 3 0-22 0 0-0 0 0-0 
200/400 2 0-8 0 0-0 0 0-0 
400 0 0-5 0 0-0 0 0-0 
JgE placebo 7,5 0-45 4 0-38 19 0-75 
200 0 0-6 0 0-0 0 0-14 
200/400 0 0-100 4 0-33 10 0-53 
400 0 0-80 0 0-16 0 0-0 
Table3a. 
Median cell numbers and 25th percentile and 75th percentile for the various treatment regimes at the end of the 
TUn in period, after 4 weeks, and after 8 weeks of treatment in the epithelium. 
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LAMINA PROPRIA run in 4 weeks 8 weeks 
median 25%-75% median 25%-75% median 25%-75% 
CDI placebo 4 1-33 5 0-7 7 2.5-30 
200 3 0-9 0 0-1 I 0-4 
200/400 7 3-14 0 0·6 0 0-2 
400 4 1-18 0 0-0 0 0-0 
cm placebo 586 446-1104 352 270-613 543 366-688 
200 446 274-804 397 147-537 386 237-814 
200/400 769 495-921 440 253-686 278 199-476 
400 405 226-741 347 271-576 355 125-1137 
CD4 placebo 416 289-644 337 211-451 372 267-749 
200 309 206-536 187 139-518 393 161-748 
2001400 479 319-766 335 161-392 300 187-506 
400 325 162-586 152 73-517 284 204-529 
CD8 placebo 376 200·655 279 188-329 186 111-399 
200 324 140-415 142 92-340 195 123-401 
200/400 292 174-603 296 216-479 155 108-229 
400 329 151-476 136 87-348 208 93-412 
CD25 placebo 10 1-35 12 8--46 30 12--49 
200 0.5 0-5 3 1--3 17 3--38 
200/400 6 0-13 7 0-43 14 6--22 
400 2 0-75 15 1--33 10 5--34 
BMKI3 placebo 6 0-18 3 1--19 8 1--25 
200 2.5 0-8 0 0-3 0 0-9 
200/400 0 0-3 0 0-13 0 0-2 
400 1,5 0-4 0-11 0 0-3 
Tryptase placebo 94 54-131 39 28-75 50 19-78 
200 86 43-117 18 1--58 17 8--68 
200/400 59 33-94 31 16-39 24 14-37 
400 66 34-79 36 13-55 19 10--35 
Chymase placebo 86 47-125 73 46-109 53 25-106 
200 69 39-139 59 27-97 46 18-86 
200/400 61 51-105 53 35-63 49 27-66 
400 62 53-75 43 27-67 25 12--37 
IgE Placebo 36 5-98 24 5--79 32 8--121 
200 6 1-43 19 4--37 II 4--27 
200/400 31 17-99 21 3--59 26 6--69 
400 9 I-52 21 14-47 9 0--27 
Table 3b. 
Median cell numbers and 25th percentile and 75th percentile for the various treatment regimes at the end of the 
run in period, after 4 weeks, and after 8 weeks of treatment in the lamina propria. 
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Epithelium 400 vs 200 + 200/400 200 +200/400 vs placebo 400 vs placebo 
CD I ~"'~ :: CD3 
CD4 
'" "''''''' CDS 
'" "'''' CD25 BMKI3 
'" Tryptase 
'" Chymase 
IgE 
Lam Prop 400 vs 200 + 200/400 200 +200/400 vs placebo 400 vs placebo 
CD I ~ ~~ 
CD3 
CD4 
CDS 
CD25 
BMK 13 
Tryptase 
'" Chymase 
19B 
Table 4. 
Statistical evaluation after 4 weeks of treatment. The biopsy data of the fluticasone 200 once daily group and the 
data of the fluticasone 200 once daily for 4 weeks followed by fluticasone 200 bi-daily for 4 weeks is pooled 
since these groups received the same treatment until! that moment. Arrows indicate significant decrease. One 
arrow: p<0.05. Two arrows p<O.Ol. Three arrows p<O.OOI. 
Epithelium 200 vs placebo 400 vs placebo 200/400 vs 400vs 400 vs 
placebo 200 200/400 
CD I +",+ t ::: '" CD3 
CD4 
"'''' "''''''' CDS 
'" "'''' '" CD25 BMK 13 
'" Tryptase Chymase 
'" 19B 
'" '" 
Lam Prop 200 vs placebo 400 vs placebo 200/400 vs 400 vs 400 vs 
placebo 200 200/400 
CD I 
'" "''''''' "'","'",'" '" CD3 
CD4 
CDS 
CD25 
BMK 13 
'" "'''' "'''' Tryptase 
'" Chymase 
'" '" '" IgE 
'" '" 
Table 5. 
Statistical evaluation after 8 weeks of treatment. 
Arrows indicate significant decrease. One arrow: p<O.OS. Two arrows p<O.OI. Three arrows p<O.OOI. 
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DISCUSSION 
Patients. 
We were surprised that out of the 300 selected patients, only sixty-five satisfied our 
conditions for inclusion of nasal complaints for more than Ih a day. This underscores the 
importance of the use of nasal symptom scores to characterize the patients objectively. 
Symptoms. 
The efficacy of Bonnal or double dosed fluticasone propionate in treating nasal symptoms in 
this, second echelon, strictly selected group proved to be no greater than that of placebo. This 
contrasts with previous reports. However, of these early studies, only Maim's study (0=22) 
was placebo controlled, wltile half of his patients showed a nasal eosinopltilia (NARES 
patients)(6), which is known to be associated with a good responds to steroids (25). In our 
study no eosinophilia was shown. Furthermore, in Maim's study. the reduction of baseline 
complaints by placebo was larger than the additional effect of steroid therapy. The efficacy of 
placebo has to be attributed to wetting the nose twice a day with the spray (26). Scadding 
reported about the clinical efficacy of topical steroids in a combined group of 371 patiens 
with allergic and non-allergic rhinitis. She concluded that topical steroids are efficacious in 
the treatment of allergic and non-allergic rhinitis. Unfortunately no distinction was made 
between allergic and non-allergic patients as they were pooled together in the seperate 
treatment groups (9). The efficacy of treatment versus placebo was not seperately tested for 
the non-allergic patients. The reported overall efficacy might perhaps be attributed to the 
known clinical efficacy in allergic rhinitis patients. Furthemlore a significant reduction in 
nasal eosinophilia was seen in the non-allergic group similar to that of the allergic group, 
again suggesting a substantial number of NARES patients. 
The only significant decrease in the percentage of symptom free days we found was for 
sneezing, not the most important complaint of our patients. For none of the other assessment 
methods (VAS, DRC mean sumscores, assessment of nasal symptoms by investigator, 
rhinoscopy) a sigltificant effect was found. A small dose dependent effect on symptoms that 
was not significant can be seen in the different graphs. Considering the fore mentioned, we 
feel that the effect of fluticasone on nasal symptoms in NANIPER patients as we selected 
them is not clinically relevant. We feel that the NANIPER patients seen by the specialists 
these days are not suffering from a cellulary mediated disease (27). Nowadays, nasal steroids 
are often used as the first line of treatment by the general practitioner before referral to a 
specialist. It is thus possible that the referred NANlPER patients are mostly the non-steroid 
responders, which agrees with our clinical experience. 
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Cells. 
The concept of NANlPER being a neurogenic inflammation, as presented by Wollf and 
others, is not supported by our findings. For one, we found no differences in the numbers of 
inflammatory cells between patients and controls (27). Two, the lack of effect of nasal 
steroids in this group while these steroids have been reported to he efficacious in induced 
neurogenic inflammation (21). 
The absence of correlation between the marked reduction in cell numbers of the 
immunocompetent cells and nasal complaints could be the result of two different phenomena. 
The groups could be too small to measure an effect on nasal complaints. However our group 
is larger than those of MaIm (n~22) (6), and Pipkorn (n~12) (8) who did find a significant 
reduction in nasal complaints. Or the reduction in cell numbers by the steroid therapy in 
NANlPER is not clinically relevant. The reported reductions in cell numbers in allergic 
rhinitis, in responds to the steroid, are preeceded by an increase of immunocompetent cells in 
response to the allergic stimulus. In NANIPER however, no significant differences were 
found, in immunocompetent cell numbers, between patients and healthy controls (27) 
Therefore it is more likely that the absence of correlation in tlus study is relevant. 
The steroid effect in the nose seems to be cell specific and not disease specific. The 
Langerhans cell seems to be most sensitive to steroid therapy, as it is in allergic rhinitis (4). 
The T -cells in the epithelium are also sensitive, but to a lesser extend. Although our 
NANIPER data suggests only a moderate effect on eosinophHs and mast cells, wluch is not in 
line with the allergic data, this is probably due to the relative absence of these cells in 
NANIPER if compared to allergic rhinitis. If, even in small numbers, eosinophils and mast 
cells are present in NANIPER patients they are also reduced. The effect of doubling the dose 
of fluticasone on the cells is more marked than the single dose effect. This is in agreement 
with data from Godthelp (4) in patients with perennial allergic rhinitis. 
The additional effect of the higher dosage of local steroid in NANIPER on the reduction in 
cell numbers has not been described before. If tlus has implications in the treatment of 
(steroid responsive) patients is questionable. 
The marked effect of a wetting agent (i.e. placebo) in NANlPER as seen by MaIm and 
Spector is not seen in this study. Our findings as far as the placebo effect is concerned are 
more in line with those of Scadding. This might reflect the change in NANlPER popUlation 
as seen by the specialist nowadays. 
To conclude, the "rhinitis" specialist is increasingly confronted with a non-steroid-responsive 
NANlPER group. Doubling the treatment dose does not have a significant effect on nasal 
symptomatology. Although there is a significant dose dependent steroid effect on nasal 
immunocompetent cells, this does not seem to be of clinical relevance. 
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One has to bear in mind that tIus is a referred and therefore selected group. In a "virgin"(no 
previous local steroid) NANIPER patient, local steroids are still first-line treatment. Topical 
capsaicin therapy might be a new therapy for the non-steroid sensitive group. 
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Chapter 5 
Intranasal Capsaicin is efficacious in Non-Allergic Non-Infectious Perennial 
Rhinitis. A Placebo-Controlled Stndy. 
H.M. Blom, J.B. van Rijswijk, I. M. Garrelds, P.G.H. Mulder, 
T. Timmermans, R. Gerth van Wijk. 
Clinical and Experimental Allergy 1997;27:796·801 
SUMMARY 
The efficacy of topical aqueous capsaicin spray in the treatment of NANIPER patients was 
studied. Several authors described capsaicin, the pungent substance in red pepper, as an 
efficacious therapy for non-allergic non-infectious perennial rhinitis (NANIPER). Repeated 
capsaicin application induces peptide depletion and specific degeneration of the unmyelinated 
sensory C-fibers in the nasal mucosa. We perfonned a placebo (NaCI 0.9%) controlled study 
with 25 NANIPER patients. Daily record charts and visual analogue scales 01 AS) were used 
for clinical evaluation. Nasal lavages were obtained before, during, and after treatment. There 
was a significant and long-tenn reduction in the V AS scores in the capsaicin group. No 
significant difference was found between the placebo and capsaicin treated groups for the 
mean group concentrations of leukotriene (LT) C.,JDJE" prostaglandin D2 (PGD2), and 
tryptase. The levels of mast cell mediators, tryptase and PGD2, and leukotrienes, mediators 
derived from a variety of inflanuuatory celis, were low at baseline and comparable with 
levels observed in nasal lavages obtained from nonnals. As involvement of inflammation 
could not be demonstrated, it is not surprising that capsaicin has no effect on inflammatory 
mediators. This suggests that inflammatory cells do not playa major part in the pathogenesis 
ofNANIPER. 
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INTRODUCTION 
The knowledge of non-allergic non-infectious peremlial rhinitis (NANIPER) or vasomotor 
rhinitis is limited. This condition is unrelated to allergy, infection, structural lesions and/or 
other systemic disease (1). The diagnosis is made by exclusion. Patients within this classifica~ 
tion may complain of symptoms such as sneezing, watery rhinorrhea and/or nasal obstruction. 
Treatment of this condition is more difficult than that of allergic rhinitis, a disease that can be 
relieved by use of antihistamines and nasal steroids. 
The pathophysiology of non-allergic rhinitis is largely unknown (I). Several hypotheses have 
been put forward. A subgroup of patients may react to cold dry air with release of 
inflrumnatory mediators from mast cells involving a l1on-IgE-dependent mechanism (2), 
Inflammatory cells appear to playa minor part in the vast majority of patient's (3). However, 
Knani reported a significant increase in tryptase levels, and increased levels of L TC4 and 
PGD2 in nasal lavage in symptomatic NANIPER patients versus control subjects. (4). 
Neurogenic mechanisms may be important since some patients, who react with watery 
discharge to spices and change of temperature, may benefit from use ofanticholinergics (5). 
Lacroix has shown that repetitive administration of capsaicin - the pungent agent in hot 
pepper - reduces nasal symptoms of patients with a rhinosinusitis, for which they undenvent 
sinus surgery, or patients suffering from a dmg-induced rhinitis (6). This reduction is 
accompanied by a decrease in positive immunoreactivity to calcitonin gene-related peptide 
(CORP) in nasal biopsies. This observation is consistent with the observation that capsaicin 
induces peptide depletion and specific degeneration of the sensory C-fibers in the nasal 
mucosa of rodents (7). Several studies have been published showing that capsaicin 
desensitization might be an important therapeutic modality in NANIPER (6,8-10). However, 
no placebo-controlled studies have been perfonned. Moreover, the reported studies lack well-
defined criteria for having NANIPER, with the risk of heterogeneity of the patients used. 
The purpose of this study was to evaluate capsaicin treatment in a placebo-controlled fashion 
using a homogeneous group of well-characterized patients suffering from NANIPER. 
Second, by measuring mediators of inflammation in nasal lavage fluid, we investigated the 
involvement of inflammation in NANIPER and the possible modulation by capsaicin. 
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MATERIALS AND METHODS 
Subjects 
Patients were admitted to the study if they had a history of nasal complaints such as nasal 
obstruction, sneezing, and rhinorrhea for a period of over 1 year which could not be attributed 
to allergic rhinitis, nasal or paranasal sinus infection, anatomical disorders affecting nasal 
function, pregnancy or lactation and/or systemic disorders (tabel 1). 
Incillsioll criteria 
- Age between 16 and 64 years, 
- Negative skin prick test: house dust mite, tree pollen mix, grass pollen mix, bijvoet. alternaria, 
aspergillus, cladosporium, penicillum, dog, cat, parakeet, mbbit, hamster, horse, guinea pig. (ALK-
Diephuis, Holland) 
- Negative Phadiatop (Phannacia, Uppsala, Sweden) 
- Symptoms for more than I year. 
- Periods of nasal discharge, sneezing and congestion for an average of at least I h pcr day for at least 5 
days during a period of 14 days. 
Erclusioll criler;a 
~ The use of systemic or inhaled corticosteroids within the previous month . 
• Use of inhaled sodium cromoglycate or nedocromil sodium within the previous month. 
~ Use of astemizole within the previous month. 
- Inability of the patient to stop taking medication affecting nasal function. 
~ A serious and/or unstable disease. 
~ Nasal surgery within the previous 6 weeks. 
~ Nasal polyps or a history of nasal polyps. 
- Significant anatomical abnomlalities affecting nasal function. 
- Nasal or paranasal sinus infection (abnonnal sinus X-ray). 
- Pregnancy or lactation 
- Abnonnal findings at physical examination 
- Abnonnallaboratory results for: 
blood: Na, K, Ca, total protein, albumin, urea, creatinine, bilirubin, alkaline phosphatase, aspartate 
aminotransferase, alanine aminotransferase, gammaglulamyl transpeptidase, hemoglobin, red blood cell 
count, plasma cell volume, mean corpuscular volume, platelets, total white blood cellcount, 
neutrophils, lymphocytes, monocytes, eosinophils, basophils. 
urine: blood, protein, glucose. 
Table I. Selection criteria for patients with NANIPER. 
They were non-smokers not using medication affecting nasal function. Patients with nasal 
polyps were excluded, since they may belong to a different pathophysiological group and 
their polyps may contribute to a higher symptom score for nasal blockage and/or rhinorrhea. 
Thirty-five patients, with the diagnosis of NANIPER, scored their nasal complaints for a 
period of2 weeks using a daily record card (DRC) (figure I) (II). In affected patients periods 
of either nasal discharge, and/or sneezing and/or congestion had to persist for an average of at 
least lh per day for at least 5 days during a period of 14 days. Coughing and coloured mucus 
production were used as indicators of upper airway infection and thus used as exclusion 
criterion. 
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Possible scores on the daily record chart 
Nasal blockage: 
(not being able to breathe freely through the nose) 
Clear nasal discharge: (runny nose) 
Sneezing 
Coughing 
Mucus production: 
(yellow, green or brown) 
o absent 
1 = between O-Ih per half day 
2 = between 1-2 h per half day 
3 = more than 2 h per half day 
0= absent 
I = less than 5 periods per half day 
2 = between 5-10 periods per half day 
3 = more than 10 periods per half day 
0= absent 
I = present 
Figure I. Scheme ofthe daily record card for defming nasal symptoms in patients with NANIPER (VMR). 
The duration of complaints during the day was used as the prime criterion for further study. 
Twenty-five of the 35 patients were found eligible for our study and participated under 
conditions of informed consent (male/female: 16/9); mean age was 36 years (18-60). 
Procedures were approved by the local Medical Ethics Committee. 
Study design 
Patients were randomised and treated with placebo (11 persons) or capsaicin (14 persons) as 
depicted in figure 2. This study was performed in a single-blind placebo controlled fashion. 
Three applications of xylometazolinehydrochloride 0, I % (OtrivinR (I mglml Zyma, Breda, 
Holland), nebulisator) were given for decongestion in each nostril. The nasal airway was 
anesthetized by 3 applications (IOmglpuff) of lidocainebase (IOOmglml) (XylocaineR 10 % 
spray (Astra, Rijswijk, Holland» in each nostril. To ensure good anesthesia a pause of 15 
minutes was introduced. Lips, columella, and philtrum were covered with petrolatum/lan-
olin/glycerin salve. Capsaicin test puff was done in an exhaust hood to avoid eye irritation. 
Patients were instructed to inhale deeply before, hold their breath during and to exhale after 
substance application. The capsaicin solution (0.1 mmolll) consisted of pelargonic acid 
vanillylamide (Fluka, Buchs, Germany) dissolved in 3 1111 alcohol (96%) and diluted in I L 
NaCI solution (0.9%) (Wolf, personal communication). For 'placebo therapy' we used NaCI 
solution (0.9%). During provocation 0.5 ml solution was sprayed in each nostril (0.15 mg 
capsaicin), Blood and urine samples were taken during visits 1 and 9 (table 1) to monitor 
changes during therapy. At every visit the subjects rated overall nasal symptoms since the last 
visit on a visual analogue scale 01 AS) (0-10 em, 0 represented absence of symptoms and 10 
represented high intensity of symptoms). DRC scoring was continued untill two weeks after 
treatment. 
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4---6 Capsaicin treatment (J,), every 2 or 3 days. Totally 7 treatments. 
6--8 Evaluation period. 2 weeks after therapy 
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t Nasal lavage during treatment (immediately after therapy) 
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Figure I. Study design. 
Nasal lavage was perfomled according to the method of Greiff (12), using a modified nasal 
pool device. Experience with nasal lavage has been obtained in several studies (13). Nasal 
lavage was performed (figure 2) with 14 ml saline, preheated to 37°C. Seven ml saline was 
instilled into each nostril. After 10 seconds, the lavage fluid was expelled and collected in 
tubes, stored on ice and centrifuged for 10 minutes at 400 x g. The supernatant was stored at 
20 ·C until analysis. 
Mediator assays 
The levels of leukotriene (L T) C.,JD41E, and prostaglandin (PG) D, were measured by 
BiotrakR and Radioimmunoassay (RIA), respectively (Amersham, UK). The limits of 
sensitivity of the assays were approximately 10 pg/ml for both assays. Cross reactivity of 
LTC41D.,!E, assay: LTC, (100%), LTD, (100%), LTE, (70%), LTB, (0.4%) and 
prostaglandins «0.006%); PGD, assay: PGD, 
(100%), PGJ, (7%), TxB, (0.3%), PGF, (0.04%) and other prostaglandins «0.02%). 
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Tryptase was detennined by RIA according to the manufacturer's instructions (Phannacia, 
Uppsala, Sweden). The detection limit was 0.5 mUlml. Cross reactivity for heparin «0.01%). 
(14) 
Statistical analysis 
V AS data during treatment were analysed using a repeated measures analysis of variance. In 
the model, time was included as a quantitative variable; the interaction between time and 
treatment group was also included. Hence, a difference in time trend between the two 
treatment groups can be estimated and tested. The within-subject (co)variance matrix of the 
residuals is supposed to be unstructured. Leukotrienes, prostaglandin D2, and tryptase are 
analysed after log transfonnation. 
Measurements after treatment (visits 9, 10, and II) were analysed separately as changes from 
baseline using t-tests, between groups (unpaired) as well as within groups (paired). DRC data 
are summarized as within patient averages over two-week periods: a first period before 
randomization/treatment, a second period after randomization (during therapy) and a third 
period after cessation of treatment. Between groups differences are tested using the Mann-
Whitney test. P values < 0.05 were considered significant. 
RESULTS 
The application of XylocaineR spray in the nasal airway was immediately followed by a 
painful sensation that was described by all subjects as most unpleasant. Patients did not 
complain of irritation of nose and lips during or after capsaicin/placebo application. 
One of the 14 capsaicin patients could not continue after three capsaicin applications because 
of influenza with fever. 
SYMPTOM SCORES 
Daily record card 
The mean score (± standard error of the mean) on the DRC of the included patients was 2.0 
(± 0.049) for blockage, 1.4 (± 0.044) for clear nasal discharge, and 1.5 (± 0.033) for sneezing 
before therapy. No significant difference was found for the individual symptoms as well as 
the mean sumscore before, during or after therapy. 
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Figure 2, TIle mean of the symptom score measured on a VAS (0-10 em, 0 represented absence of symptoms 
and 10 severe intensity of symptoms) for nasal complaints. Error bars indicate 2.07SE. 
Visual analogue scale 
The mean of VAS is shown in figure 3. There was no significant difference between the 
groups in the V AS score before treatment. During treatment a smaller trend with time (-0040 
per two days) was seen in the capsaicin group than in the placebo group (+0.019 per two 
days), the difference being significant (p~0.0007). At visits 9, 10 and II the difference 
between the groups remained significant. Also, the difference from baseline remained 
significant within the capsaicin group from visit 9 on. This was not the case in the placebo 
group (figure 2). 
Nasa/lavage 
The median return, of the 14 m1 Nael instilled, was 10 mI. 
The mean baseline levels (± standard error of the mean) of tryptase, LTC.,JD.,JE" and POD, 
were 1.98 (± 0.422) mUlml, 7.70 (± 3.10) pg/ml, and 16.2 (± 2.00) pglml, respectively, in the 
nasal lavage fluid of the treated group. 
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The mean baseline levels (± standard deviation) of tryptase, LTC.,JD.,IE" and PGD, were 
2.09 (± 0.611) mUiml, 2.62 (± 1.12) pg/ml, and 16.4 (± 2.85) pg/ml, respectively, in the nasal 
lavage fluid of the placebo group. The mean baseline levels (± standard deviation) of 
tryptase, LTC.,JD.,IE" and PGD, were 2.09 (± 0.6\\) mD/ml, 2.62 (± 1.12) pg/ml, and 16.4 (± 
2.85) pg/ml, respectively, in the nasal lavage fluid of the placebo group. 
During treatment no significant difference in time trend between the two groups was fOlUld 
for the concentrations oftryptase, LTC,ID.,IE" and prostaglandin D, in the nasal lavage fluid. 
At visits 9, 10 and 11 no significant changes from baseline or significant differences between 
the groups were found either. 
Safety dala 
None of the patients had a relevant change of blood and/or urine chemistry outside the 
nonnal range. 
DISCUSSION 
There is a dearth of infomlation regarding the pathophysiology of NANIPER. The limited 
understanding of this condition hampers the development of therapeutic modalities. An 
imbalance in the nonadrcncrgic, noncholinergic peptidergic neuronal system has been 
proposed as the underlying mechanism ofNANIPER (15). Treatment with capsaicin may fit 
in with this hypothesis (16). This study showed that seven treatments in a 14·day period 
ameliorated symptoms during a foHow-up of 9 months. It is possible that reduction of symp-
toms will last longer; however, we feel that it is unethical to maintain a placebo~treatment for 
many months, so we ended the trial after nine months of follow-up. Tlus longtenn placebo-
controlled study con finned the efficacy and safety observations made during open 
uncontrolled studies (6,8-10). 
The study has several limitations. The study was designed in a placebo·controlled double 
blind fashion. However, we did not expect that we could blind the treatment for the patients, 
as tlus was considered impossible by several authors. In contrast to our expectations patients 
complained severely about the Xylocaine® spray. Therefore they were not able to 
discriminate between the active and the placebo substance. Furthermore the immediate 
respons to treatment did not pennit us to discriminate between patients receiving capsaicin or 
placebo. 
Second, since we used saline as placebo treatment rather than the solution used for dissolving 
capsaicin (which contained saline with 0.3 % alcohol 96%), we cannot exclude the possibility 
that an effect of alcohol biased the therapeutic efficacy of capsaicin. It is, however, unlikely 
that instillation of these nunute quantities of alcohol will induce a significant reduction in 
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nasal symptoms during 9 months. Moreover, saline containing a fivefold dose of 1.5% 
alcohol has no effect on nasal conductance (17). 
Finally we encountered a discrepancy between the reduction in V AS score and the absence of 
effect on DRC, which might be explained by the difference in nature between the scoring 
methods. The V AS scores the severity of the complaints whilst the DRC scores the duration 
ofthe complaints. 
Furthermore, as the study proceeded patients compliance (in filling in the DRC) seemed to 
grow less, since scoring the DRC is a time consuming and daily returning task. At the end of 
the trial some patients even reported that they had filled in their DRCs all at once just prior to 
their hospital visit. 
In contrast, the VAS score is a quick and easy method for the patient. Also the fact that the 
placebo group showed no evidence of improvement in the VAS combined with the finding 
that the duration of the treatment's effect is quite impressive and consistent with what all the 
previous uncontrolled studies have suggested (6,8-10), we feel the VAS is more reliable than 
the DRC. 
In animals capsaicin stimulates sensory C-fibers with the resultant release of substance P (SP) 
(7,18) and calcitonin gene related peptide (CORP) (19). However, after several stimulations 
this is followed by depletion of these fibers and results in desensitisation to capsaicin and 
other stimuli (16). As tachykinins (20) and capsaicin (21) induce the recruitment of inflam-
matory cells in the nose in allergic rhinitis and SP releases histamine and TNF-alpha from 
peritoneal mast cells in animals (22), capsaicin may modulate inflammation of the nasal 
mucosa. The levels of tryptase, PGD2, and leukotrienes, mediators derived from several 
inflammatory cells such as eosinophils, basophils, and mast cells (23,24), were low at 
baseline and comparable with levels observed in nasal lavages obtained from normals (C. de 
Graaf-in 't Veld, submitted of personal conununication). This contrasts with the results 
presented by Knani (4) However, 6 out of 14 patients in Knani's study showed a prominent 
eosinophilia in nasal secretions and may have been NARES patients. Our data concords with 
the findings of Roche, however tlus paper describes the results in asymptomatic patients. As 
involvement of inflammation could not be demonstrated, it is not surprising that capsaicin has 
no effect on inflammatory mediators. Perhaps the absence of inflammation, also 
demonstrated in a recent study (3), is an explanation of the moderate efficacy of nasal 
steroids in non-allergic rhinitis. 
To conclude, capsaicin is an efficacious substance in the treatment of NANIPER. In our 
placebo-controlled study a therapeutical cffect lasted more than 9 months. No effect was 
found on inflammatory mediators. No adverse side effects were noted. 
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Chapter 6 
The Long Tenn Effects of Capsaicin Aqueous Spray on the Nasal Mucosa. 
H.M. Blom. L. A. F. M. Severijllen, 1. B. Van Rijswijk, P.G.H. Mulder, 
R. Gerth van Wijk, W. 1. Fokkells. 
Clinical and Experimental Allergy, 1998, in press. 
SUMMARY 
The long ternl effects of capsaicin spray on the nasal mucosa are shldied. Capsaicin has been 
shown previously to reduce nasal complaints in patients with a non-allergic non-infectious 
perennial rhinitis. Proposed pathophysiologic mechanisms for non-allergic non-infectious 
perennial rhinitis include a chronic inflammatory disorder of antigenic or neurogenic nature as 
well as the possibility of a fimctional neuronal disorder. We hypothesized tllat the benificial 
effect of capsaicin might be the result of a down regulation of inflanuuation (by a reduction of 
inflammatory cells) or through a modulation of neural tissue density. Patients were treated with 
either a placebo or capsaicin spray solution delivering 0.15 milligrams of capsaicin per nostril 
once every second or third day for a total of seven treatments. Both sides were treated each visit. 
Biopsies were taken before, 2 weeks after, 3 months after, and 9 months after the treatment 
period. Immunohistochemical staining of the biopsy specimen was perfonned to ascertain the 
effect of treatment on immunocompetent cell densities (quantitative) and neural tissue densities 
(semi-quantitative) in the nasal mucosa. Nasal complaints were significantly reduced in the 
capsaicin treated group. The number of CDl+, CD25+, CD3+, CD68+, BMK13+, IgE+, 
Tryptase+, and Chymase+ cells did not significantly differ between capsaicin and placebo group. 
No significant differences between both groups were fotUld in palHleurogenic staining of nasal 
mucosa using neurofilament and synaptophysine. Capsaicin aqueous nasal spray has been 
shown previously to reduce nasal complaints without affecting cellular homeostasis or overall 
neurogenic staining upto 9 months after treatment, furthemlore immunocompetent cells are 
not involved in non-allergic non-infectious perennial rhinitis. 
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INTRODUCTION 
In a double blind placebo controlled study we recently demonstrated that capsaicin is highly 
effective in controlling non-allergic non-infectious rhinitis (l), A long-lasting relief in 
symptoms was obtained for at least 9 months. 
Capsaicin is the pungent agent in red peppers. Its mode of action is well documented in 
rodents, where it affects mainly the thin unmyelinated sensory nerve fibers. It causes initial 
stimulation (with release of endogenous neuropeptides), followed by desensitisation to 
capsaicin and other sensory stimuli (2) With higher doses long term functional or even 
morphological ablation of the thin sensory neurons occur (3). In humans the effect of 
capsaicin has not been fully documented (4). Moreover the pathophysiologic mechanism for 
non-allergic non-infectious perennial rhinitis is not understood. Proposed mechanisms include 
a chronic inflammatory disorder of antigenic or neurogenic nature, or a functional neuronal 
disorder (5,6). 
To study wether capsaicin reduces inflanm13tion or modulates nasal neuronal tissue densities 
we performed a nasal biopsy study in 24 patients with non~allergic non~infectious perennial 
rhinitis. Cells were quantified per square millimeter and the sections stained with neuronal 
markers were scored semi~quantitatively for morphometric changes. 
MATERIALS AND METHODS 
Subjects 
Patients were admitted to the study if they had a history of nasal complaints such as nasal 
obstruction, sneezing, and rhinorrhea for a period of over 1 year which could not be attributed 
to allergic rhinitis, nasal or paranasal sinus infection, anatomical disorders affecting nasal 
function, pregnancy or lactation andlor systemic disorders (7,8) They were non~smokers not 
using medication affecting nasal function. Patients with nasal polyps were excluded, since 
they may belong to a different pathophysiological group and their polyps may contribute to a 
higher symptom score for nasal blockage and/or rhinorrhea. 
Study design 
Thirty-five patients, with the diagnosis of non-allergic non-infectious pere.nnial rhinitis, 
scored nasal blockage, clear discharge, sneezing and coughing on a 4 point scale and mucus 
production (absent or present) for a period of2 weeks using a daily record card (1,7,8). Mucus 
production or coughing were used as indicators of upper airway infection. If present they led 
to exclusion of the patient. Patients were included in this study if periods of clear nasal 
discharge, sneezing and nasal blockage persisted for an average of at least 1h per day for at 
least 5 days during a period of 14 days. The duration of complaints during the day was used as 
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the prime criterion for further study. Twenty-five of the 35 patients were found eligible for 
our study and participated under conditions of informed consent (male/female: 16/9); mean 
age was 36 years (18-60). One of the 14 capsaicin patients could not continue after three 
capsaicin applications because of influenza with fever. 
Procedures were approved by the local Medical Ethics Committee. 
Patients were randomised in a double-blind placebo controlled fashion and treated with 
placebo (II persons) or capsaicin (14 persons). A total of seven treatments over a period of 
two weeks were given. 
1 lll1111 1 1 
I I I I I 
Week 0 2 4 6 8 18 
Time schedule of hospital visits, Every visit a visual analogue scale score was obtained 
J : indicates either capsaicin treatment (n= 14) or placebo (n= II), every 2 or 3 days. 
! : indicates biopsy moment 
1 
I 
42 
Figure I. Study design. During the entire study period patients scored their nasal complaints such as nasal 
blockage, clear discharge, sneezing, coughing and mucus production on a daily record card. After the first 2 
weeks (0·2, run in) patients with sufficient nasal complaints (> I hour/day for at least 5 days during the 14 days 
period) were selected. Mucus production and coughing were used as indicators of upper airway infection. If 
present they led to exclusion of the patient. A biopsy was taken in included patients. Weeks 2A were used to 
allow healing of the nasal mucosa before treatment. During weeks 4·6 a 10la1 of 7 treatments was given. During 
the evaluation period three nasal biopsies were taken. 
Treatment procedure 
The nose was decongested with Xylometazolinehydrochloride 0, I % and anaesthetised with 
lidocaine base-spray (lOOmg/ml). Capsaicin aqueous nasal spray (0.15 mg) or placebo was 
instilled in each nostril (I). The application of XylocaineR spray in the nasal airway was 
immediately followed by a painful sensation that was described by all subjects as most 
unpleasant. Patients did not complain of irritation of nose and lips during or after capsai· 
cin/placebo application. At every visit the subjects rated nasal symptoms on a visual analogue 
scale (0-10 cm, 0 represented absence of symptoms and 10 represented high intensity of 
symptoms). Daily record card scoring was continued for up to two weeks after treatment (1). 
Nasal biopsies were taken four times. At the run-in period, and after 2 weeks, 3 months, and 
9 months after the treatment period (figure I). 
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After randomisation of the biopsy side, specimens of nasal mucosa were taken from the lower 
edge of the inferior turbinate, about 2 em posterior to the front edge, using a Gerritsma 
forceps with a cup diameter of 2.5 mm. (9). Local anaesthesia was obtained by placing a 
cotton-wool carrier with 50 mg of cocaine and one drop of adrenaline (I: I 000) under the 
inferior turbinate without touching the biopsy site. The specimens were embedded in Tissue-
Tek II D.C.T. compound and frozen immediately. 
Blood: (Na, K, Ca, total protein, albumin, urea, creatinine, bi1irubin, alkaline phosphatase, 
aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, 
haemoglobin, red blood cell count, plasma cell volume, mean corpuscular volume, platelets, 
total white blood cell count, neutrophils, lymphocytes, monocytes, eosinophils, basophils) and 
urine: (blood, protein, glucose) samples were taken during visits 1 and 9 to monitor changes 
during therapy. 
Staining procedures 
Monoclonal antibodies (mAb) directed against synaptophysine, neurofilament, CDI, CD3, 
CD25, CD68, IgE, MBP, chymase, and tryptase (table 1) were used together with the super 
sensitive inmlUno-alkaline phoshatase (ss-APAAP) method. Sections of nasal mucosa were 
Antibody 
OKT6 
leu4 
KIM-6 
2Fll 
Sy38 
IL-2r 
BMK13 
B7 
G3 
Specificity 
CDI 
CD3 
CD68 
Neurofilament 
Synaptophysine 
IgE 
cm5 
MBP 
Chymase 
Tryptase 
Titre Source 
1:100 Dept. Immunology, Erasmus University, Rotterdam 
1:25 BDH, Dorset, UK 
1:100 Behring, Rijswijk, NL 
1:50 Sanbio, Uden, NL 
1:20 Dakopatts, lTK, Uithoom, NL 
1:250 Central laboratory of the Netherlands Red Cross Blood 
Transfusion service (CLB), Amsterdam, NL 
1:150 BDH, Dorset, UK 
1:200 Sanbio, Uden, The Netherlands 
1:100 Chemicon, Temecula, Calif, USA 
1:250 Chemicon, Temecula, Calif, USA 
Table 1. Monoclonal antibodies used to stain biopsy specimen. 
transf~rred to poly-L-Iysine-coated microscope slides, dried, and fixed in acetone for 10 min 
at room temperature. They were next rinsed in phosphate-buffered saline (PBS, pH 7.2), 
placed in a half-automatic stainer (Sequenza, Shandon), and incubated with l1onna1 goat 
serum (CLB, Amslerdam, The Netherlands) for 10 min. Following this the slides were 
incubated with the mAb for 60 min at room temperature. The sections were then rinsed again 
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in PBS for 10 min and incubated for 30 min with a goat anti-mouse (l :50) biotin, rinsed 
successively in PBS, incubated with streptavidin alkaline phophatase supersensitive (I :50) 
(Biogenex, Klinipath, Duiven, The Netherlands) for 30 min at room temperature, rinsed in 
PBS and TRIS buffer (PH 8.5), and incubated for 30 min with a new fuchsin substrate 
(Chroma, Kongen, Germany). Finally, sections were rinsed with distilled water, 
counterstained with Gill's haematoxylin and mounted in glycerin-gelatin. Control staining was 
perfonned by substitution with PBS and incubation with an irrelevant mAb of the same 
subclass. 
Light-microscopic evaluation 
Stained cells were quantified ("blinded") in two sections of each biopsy specimen. The 
epithelium and lamina propria were evaluated separately. The total surface area of a section 
and its main parts (Le. the epithelium and the lamina propria) were estimated with the use of 
the Kontron Image Analysis System Videoplan. The number of cells/mm' was calculated for 
the epithelium and the lamina propria. The intensity, number and dimensions (width and 
length) of neuronal staining was semi-quantified by 3 separate observers. Biopsies were 
ranked I to 24 by continuously comparing the biopsies amongst another until all were ranked, 
by each seperate observer. In practice: a section would be taken (at random), evaluated and 
put down. The next section would be taken (at random) and be graded for stronger or weaker 
staining compared with the previous section. The next section would be stronger, weaker, or 
in between the two previous sections. At the end all sections would be "on the table" and the 
weakest stained section would receive rank 1 and the strongest stained section would receive 
rank 24. 
Statistical analysis 
The non-parametric Mann-Whitney V-test was lIsed to compare the differences in cell counts 
between the groups. A p-value < 0.05 was considered to indicate a significant difference. 
The Spearman rank correlation's between changes in cell numbers and the changes in the 
visual analogue scale scores per randomisation group were calculated. 
For the inter-observer variation the rank correlation between the rankings of any two 
observers was calculated per visit for synaptophysine and neurofilament. Also differences in 
ranking between any two observers were calculated. The mean rank averaged over the three 
observers was used to compare the two treatment groups per visit, using the Mann-Whitney V 
test. 
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RESULTS 
Biopsies 
The sections of the nasal mucosa had an average surface area of2.0 mm2 and usually showed 
a lining of ciliated columnar epithelium with or without goblet cells and! or partially stratified 
cuboidal epithelium. The lamina propria consisted usually of a looser sUbepithelial cell-rich 
layer with mucous glands and a deeper collagenous cell-poor layer. All sections were 
sufficiently deep to assess both layers. The sections were generally of good quality. No 
structural damage to the mucosa was seen after capsaicin treatment (thickness of the 
epithelium, thickness of basal membrane, number and size of glands) 
InjlammalOlJI cells 
The results are shown in tables 2a and 2b. The mAb-ss AP AAP staining showed red cells 
against a blue counterstained background. T -lymphocytes, small round cells, were abundantly 
present in the epithelium as well as the lamina propria (figure 2, page 103). Sometimes 
clusters ofT-cells were found in the epithelium or lamina propria (500-1000). The occurrence 
of these clusters did not differ between the groups. Langerhans cells, large dendritic cells, 
were found mostly in the epithelium. Only a few were present in the lamina propria. Mast 
cells were found mostly in the lamina propria and hardly ever in the epithelium (fignre 3, page 
103). Eosinophils were hardly ever present in our material. Sometimes moderate infiltrates 
were found in the mucosa. The occurrence did not differ between the groups. The CD68 
positive ceHs were large cells with a bright staining cytoplasm. This cell type was found to be 
equally distributed in both layers. No significant changes were found between treatment and 
placebo for any of the cells. 
Neuronal staining 
Synaptophysine and neurofilament staining showed red fibers cut at different angles (figure 4 
and 5, page 103). The rank correlation between any 2 observers varied from r = 0.8 to r = 
0.96. The differences in ranking between any 2 observers varied between -8 and II, with a 
mean and a median (almost) equal to zero, as expected. No significant differences between 
the two treatment groups were found for either synaptophysine or neurofilament staining. 
Blood and urine 
No significant changes were found for any of the blood or urine parameters. 
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Epithelium Run in 2 weeks 18 weeks 42 weeks 
TreatmelJ( plac caps Plac Caps plae caps plac Caps 
CD! 379 341 451 447 275 355 230 350 
25% 346 159 221 269 211 261 93 100 
75% 846 425 970 791 591 529 278 621 
cm 1457 624 943 821 732 1340 1244 1339 
25% 561 438 378 677 572 737 762 301 
75% 2105 1432 1049 1557 1013 2992 1955 2667 
CD25 84 34 59 86 52 50 44 36 
25% 53 15 29 32 16 30 18 19 
75% 128 92 67 176 182 195 64 129 
CD68 455 578 512 587 480 1037 595 487 
25% 228 340 334 379 305 472 421 377 
75% 1934 800 709 856 1440 2071 875 1842 
BMKI3 8 3 25 9 9 7 13 3 
25% I 2 0 2 0 0 0 0 
75% 65 22 29 110 67 152 56 37 
Tryptase II 6 II 25 18 27 15 13 
25% 0 4 0 0 0 II 0 0 
75% 26 17 50 115 109 100 51 45 
Chymase 0 3 16 12 7 15 14 36 
25% 0 0 0 0 0 2 3 0 
75% 8 56 26 61 18 42 19 105 
IgE 74 123 57 36 153 56 29 20 
25% 9 6 0 3 7 2 0 0 
75% 311 206 420 160 182 269 344 185 
Lamina propria Run in 2 weeks 18 weeks 42 weeks 
Treatment plae caps Plae Caps plae caps plae Caps 
CDI 58 31 27 52 48 35 9 18 
25% 51 15 18 16 21 17 9 18 
75% 67 63 54 79 70 95 46 90 
Cm 1372 591 616 1151 964 1262 856 1386 
25% 1055 407 366 576 759 632 433 639 
75% 3191 1237 1125 1457 1451 2172 2139 2552 
CD25 50 36 47 82 24 43 28 45 
25% 30 20 23 41 17 8 13 II 
75% 93 75 79 141 51 97 54 83 
CD68 384 321 267 477 320 573 380 544 
25% 200 257 161 395 278 274 244 300 
75% 911 675 752 571 831 984 524 965 
BMKI3 23 II 16 51 18 15 16 39 
25% 6 8 5 21 2 6 13 8 
75% 45 43 53 89 52 77 38 93 
Tryptase 199 192 194 302 212 205 171 248 
25% 98 60 94 177 94 113 121 169 
75% 281 402 494 445 387 395 213 479 
Chymase 158 164 146 282 178 285 148 285 
25% 100 93 62 112 123 119 98 189 
75% 270 377 334 479 410 343 273 427 
IgE 102 47 112 140 131 117 85 150 
25% 55 30 45 75 34 36 35 55 
75% 281 265 234 160 390 253 180 316 
Table 2a and b, Median cell numbers (in the epithelium and the lamina propria) and 25th percentile and 75th 
percentile for capsaicin (caps) and placebo (plac) treatment at the end of the run in period, after 2 weeks, 18 
weeks and 42 weeks after treatment. 
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DISCUSSION 
The effect of capsaicin on Basal complaints and cellular mediators has already been described 
(l). To summarise, a nine months amelioration of nasal complaints was seen without an effect 
on cellular mediators. 
The mode of action of capsaicin is not clear, neither is the aetiology of non~allergic non~ 
infectious perennial rhinitis. Proposed mechanisms for non-allergic non-infectious perelll1ial 
rhinitis include the possibility of a chronic inflammatory disorder. We hypothesised that the 
beneficial effect of capsaicin-treatment could be the result of down-regulation of the 
inflammation, resulting in a reduction in the number of inflanunatory cells. Knowledge on the 
effect of capsaicin provocation on nasal cellular homeostasis is limited to lavage studies 
following a single capsaicin dose. Philip (10) described biphasic inflammatory-cell influx 
with neutrophils, eosinophils and mononuclear cells (in nasal lavage) upto 4 hours following 
capsaicin provocation. Roche (4) described an increase in neutrophils but not in other cells 10 
min. after capsaicin challenge. Whether or not this reflects a 'wash out' by increased nasal 
secretion, or an increase in mucociliary activity which could sweep cells out of the sinuses, or 
a transmigration of immunocompetent cells from the vessels through the nasal mucosa in the 
nasal lumen remains open for discussion (10). Our nasal biopsy study circumvents the '\vash 
out problem" since it allows shldy of all mucosal layers. In a pilot study with 3 patients 
(unpublished data) we learned that 2 weeks after the last capsaicin treatment a new steady 
state in nasal symptomatology was reached. We hypothesised that if a correlation was to be 
found between the number of immunocompetent cells and nasal symptomatology tills would 
be the moment to ascertain it. We realised that we would miss an opportunity to study the 
direct effect of capsaicin on nasal immunocompetent cells ("provocation effecf l ) since two 
weeks after cessation of the neurogenic stimulus the supposed capsaicin induced neurogenic 
inflammation may have withered and will therefore not be detected. A biopsy taken directly 
after the first treatment was not considered opportunistic, because six more treatments would 
follow. 
No correlation was found between nasal symptomatology and any of the immunocompetent 
cells, for any of the biopsy moments. Nor did we find any significant cellular differences 
between the placebo and the treatment group for any of the biopsy time points. This could 
mean that, a): cells are not an intregral part of the Ileurogelllc response, or b): as Greiff stated 
"The animal concept of neurogenic inflammation is not valid for the nasal airway, not even in 
inflamed airways when a neural hyperresponsiveness has developed tl • (11) 
The absence of correlation between cells and symptoms which is congruent with our previous 
study in which a reduction in nasal immunocompetent cell numbers was found in a group of 
non-allergic non-infectious perennial rhinitis patients treated with fluticasone aqueous nasal 
spray without a reduction in nasal symptomatology (8), the absence of significant differences 
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in the number of immunocompetent cells between capsaicin and placebo group, and the 
absence of an increase in cellular mediators (as a sign of cellular activation) following 
capsaicin challenge (1,12) raises the question of the relevance of the increase of 
immunocompetent cells in nasal lavage after capsaicin challenge. 
We, again conclude that immunocompetent cells are not involved in non-allergic non-
infectious perennial rhinitis (7,8). 
Reports on the effect of capsaicin (rea(ment on neuronal tissue are not consistent. Lacroix 
(13) showed a 50% decrease in CGRP-like immunoreactivity after capsaicin treatment of 16 
patients with a drug induced rhinitis suggesting depletion or atrophy of the umnyelinated 
sensory nerve fibers. In contrast, Wolf (14) in a study of 123 patients failed to show any 
reduction of peptidergic neurones within the nasal mucosa of 16 selected (uncharacterised) 
patients. He suggested a blockage of receptors as the mode of action. To quantity neuronal 
staining is difficult and often open to discussion, as nerve fibers may have a different diameter 
and can be cut at different angles, resulting in an abundant variation in staining morphology 
(figures 4 and 5). We used a continuous ranking system. We found a very high Kappa for 
interobserver variability suggesting a reliable quantification method. No significant 
differences were found between placebo and treatment group for neurofilament or 
synaptophysine staining. These antibodies are pan-neurogenic markers. They do not allow 
discrimination between the adrenergic, the cholinergic and or the peptidergic system. The data 
thus, allows us to conclude that capsaicin does not induce gross changes in nervous tissue in 
the nasal mucosa in non-allergic non-infectious perelmial rhinitis patients. Other signs of 
capsaicin induced mucosal damage were not seen, and inflammatory cell densities were not 
affected. Possible changes in the peptidergic system (the supposed site of action of capsaicin) 
might not have been detected with these pan-neurogenic markers. 
To conclude capsaicin aqueous nasal spray does significantly improve nasal symptomatology 
in non-allergic non-infectious perennial rhinitis patients, without affecting cellular 
homeostasis or overall neurogenic staining upto 9 months after treatment. 
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Chapter 7 
General Discussion 

GENERAL DISCUSSION 
In the introduction the goals of tlus thesis were outlined. Stepwise I will discuss the answers 
and elaborate on future research. 
Did we accurately define, select, and study a group of NANIPER patients? 
Unfortunately, there is no litmus test for NANlPER. The diagnosis is and was made above all 
through exclusion of the known causes. This means that the studied patient group is probably 
a melting pot of patients suffering from nasal complaints, with presumably variable 
pathogenesis. To study, select and define a group of patients, and more, measure the effects of 
interventions, positive selection criteria needed to be fonnulated. Several methods have been 
used to quantify nasal complaints. Basically these methods can be subdivided into two scoring 
methods. Either the intensity (I) or the duration of the nasal complaints is graded. The grading 
system can either be continuous such as the visual analogue scale (V AS) or it can be semi-
quantitative. From previous studies and pilot studies it was learned that a semi-quantitative 
daily record card (DRC), scoring duration of complaints together with the V AS suited our 
purposes most. It allowed the use of stringent selection criteria as suggested by Mygind (2), 
patients did not experience the daily returning task of filling in the record card as too great a 
burden, and the use of the VAS allowed for a sensitive statistical analyses of the 
interventional effects. During the presented studies it was noticed that the longer the period 
between the visits the weaker the compliance of the patients in filling in the DRC (3, 4). We 
have now set a maximum of two weeks between patient and researcher contact in our studies 
to monitor patient compliance. For the evaluation of interventional effects the VAS proved to 
be most sensitive (3, 4). This has resulted in the use of the DRe as a tool to include patients; 
the V AS is used to monitor interventional effects in present studies. 
It seems that the above stated goal was reached. A key question however is; '\vas a 
representative group of NANlPER patients gathered?" We feel they were representative for 
the NANlPER patients seen nowadays in the second echelon (3, 4). Doubts remain wether 
this group is also representative of the first echelon NANIPER patient. The increased 
prescription of local steroids in the first echelon, during the last decade, to which a subgroup 
of NANlPER patients were reported to respond well, may have biased the studied group as 
these patients were probably not referred to the second echelon. 
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Are inflammatory cells involved in the pathogenesis ofNANIPER? 
The involvement of inflammatory cells is well accepted in allergic rhinitis (5-11). In 
NANIPER the involvement of inflammatory cells is under discussion. Although some 
pathophysiological concepts, such as local allergy (12) and NANIPER induced by the non-
adrenergic non-cholinergic system (NANC) (13-20), may agree with an involvement of 
inflammatory cells ot\lers such as autogenic imbalance (21-25) and dys- or hyperaesthesia 
(Togias, personal communication) do not. 
Knani reported increased mediator levels in NANIPER suggesting an involvement of 
inflammatory cells (26). Mast cells were implicated by Abe and Terrahe (27, 28). However, 
Braunstein and Hua failed to find any evidence for neurogenically induced mast cell 
degranulation (29, 30). 
Several methods are available to study nasal immunological cells. All three were used in the 
presented studies. To ascertain the percentage of NARES patients in the studied patients 
group a nasal brush was taken allowing quantification of eosinophils in the harvested cells. By 
measuring mediators of inflammation in nasal lavage fluid, inflammatory mediators in 
NANIPER were investigated. Biopsy specimens were taken to allow study of the deeper 
layers of the nasal mucosa (31). In chapter 2 and 3 a comparison was made of the nasal 
mucosa cell densities in NANIPER patients versus asymptomatic controls. No significant 
differences were found. Moreover we failed to find a single NARES patient in our group. The 
question then arises as to whether this immunohistochemical evaluation method is sensitive 
enough to detect significant differences between the groups. The calculated ratios between the 
geometric means of both groups indicating threshold significance at the 5% level are within 
the range found in patients with chronic allergic rhinitis (9, 10, 32). In these studies, which 
compare symptomatic allergic patients with asymptomatic controls, cellular differences 
between patients and controls were indeed found, while the distribution of the number of 
immunocompetent cells/nun2 was in the same order of magnitude as in this NANIPER study. 
It seems justified to assume that if significant mucosal inflammation would be present, it 
would have been detected. The lack of differences in cell numbers does not exclude a 
functional cellular involvement. However, a relation between the number of 
immunocompetent cells and nasal complaints in NANIPER patients could not be ascertained 
(3, 4). A significant reduction of inununocompetent cells in the nasal mucosa of NANIPER 
patients treated with nasal steroids (fluticasone aqueous nasal spray) was not accompanied by 
a reduction in nasal complaints (3) and, vice versa, a significant reduction in nasal complaints 
in a group of NANIPER patients treated with topical capsaicin aqueous nasal spray was not 
accompanied by a change in inflammatory mediators (4) or a reduction in the numbers of 
inflammatory cells. Considering the aforementioned we conclude that inflammatory cells are 
not involved in NANIPER. 
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Were local steroids effective, and if so, how arc they effective in NANIPER, and in which 
subgroup? 
The efficacy of nonnal or double dosed fluticasone propionate in treating nasal symptoms in 
this, second echelon, strictly selected patient group proved to be no greater than that of 
placebo. This contrasts with previous reports. However, of these early studies, only MaIm's 
study (n~22) was placebo controlled, while half of his patients showed a nasal eosinophilia 
(NARES patients) (33), which is known to be associated with a good responds to steroids 
(34). In our study no eosinophilia was shown. Furthennore, in Maim's study, the reduction of 
baseline complaints by placebo was larger than the additional effect of steroid therapy. The 
efficacy of placebo could be attributed to wetting the nose twice a day with the spray (35). 
Scadding reported about the clinical efficacy of topical steroids in a combined group of 371 
patients with allergic and non-allergic rhinitis. She concluded that topical steroids are 
efficacious in the treatment of allergic and non-allergic rhinitis. Unfortunately no distinction 
was made between allergic and non-allergic patients as they were pooled together in the 
separate treatment groups (36). The efficacy of treatment versus placebo was not separately 
tested for the non-allergic patients. The reported overall efficacy might perhaps be attributed 
to the known clinical efficacy in allergic rhinitis patients. Furthermore a significant reduction 
in nasal eosinophilia was seen in the non-allergic group similar to that of the allergic group, 
again suggesting a substantial number of NARES patients. 
We have tried to correlate cells and nasal complaints. A combined average score for numing, 
blockage and sneezing was calculated for the fust week (run-in) and for the last study week 
(prior to the Jast visit). No correlation was fOWld between the calculated scores and changes in 
the mucosal densities of lymphocytes (CD3, CD4, CD8) and activated lymphocytes (CD25), 
mast cells (tryptase and chymase), JgE positive cells, and eosinophils (BMK13 and EG2), and 
CD 1 positive cells for any of the randomization groups. However when the partial correlation 
(the correlation between cells and complaints corrected for the possible treatment effects for the 
entire patient group) was calculated, a weak (0.38 and 0.38) but significant (0.007 and 0.008) 
partial correlation was found for CD! in the lamina propria and for BMK13 (eosinophils) in the 
epithelium consecutively. Considering the weak correlation, the clinical relevance of these 
findings is questionable. 
To conclude: steroids are not effective in ameliorating nasal complaints in this group of 
NANIPER patients. Care has to be taken to extrapolate this data to the patients seen in the 
first echelon of which a subgroup (e.g. NARES) is reported to respond to steroid treatment. 
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Is local capsaicin therapy effective in NANIPER? What could be the working 
mechanism? 
Capsaicin is the pungent agent in sharp food such as red peppers. This chemical has the ability 
to stimulate sensory nerve fibers, especially nonmyelinated c-fibers that act predominantly as 
nociceptors. On acute exposure to capsaicin, these fibers generate action potentials; at the 
same time, they are stimulated to release neuropeptides that are stored in granules, at nerve 
endings. These include tachykinins, CGRP, GRP, and possibly others. When capsaicin is 
applied chronically and/or at high doses at nerve endings, defunctionalization occurs. 
Proposed mode of actions of capsaicin include; vallilloid receptor modulation (capsaicin 
receptor) (37), destruction of the cells of the c-afferent system (38, 39) and/or depletion of 
neuropeptides (19, 40). 
Several studies have been published showing that capsaicin desensitization might be an 
important therapeutic modality in NANIPER (13, 16, 37, 40-42). However, no placebo-
controlled studies have been perfornled. Moreover, the reported studies lack well-defined 
criteria for having NANIPER, with the risk of heterogeneity of the patients used. 
In chapter 5 and 6 the effects of local repeated capsaicin versus placebo applications in a well-
defined group of 24 NANIPER patients is described. We were able to show in a double-blind 
placebo controlled fashion that capsaicin treatment ameliorated nasal symptoms for at least 
nine months without affecting nasal mucosal cell and/or general nerve densities and/or 
inflammatory mediators. 
Can it now be concluded that the therapy for NANIPER is found? The treatment period lasts 
2 weeks during which 7 treatment visits of an average of 1 hour are required. Surgery aimed 
at a reduction of the inferior turbinate takes just one treatment visit and is reported to relieve 
nasal symptoms for a period of I-year (43). The vidian neurectomy propagated by Golding 
and Wood in the early sixties has more recently been reported to reduce nasal complaints in 
92% of the patients. TillS study extended over a 5-year period (44). The procedure also 
requires just one treatment visit. Unfortunately the vidian neurectomy is not very effective in 
relieving congestion whilst the surgery of the inferior turbinate does not relieve the runny 
nose and/or sneezer and not all reports present such good results (45, 46). Moreover both 
teclmiques seem crude and could be considered as 'Ioverdoing if' and serious complications 
were reported (blindness, adhesions and atrophic rhinitis). Hence the interest in capsaicin. It 
must, however, be obvious that a lot of work needs to be done to optimize the capsaicin 
treatment and dosage scheme. One could consider a "rush treatment" during the first 
treatment visit (e.g. 5 treatments in one morning) with monthly or bi-monthly maintenance 
visits. Another interesting scheme is the one suggested by Eberle (47) in which the patients 
apply a low-dose capsaicin solution 3 times a day during a period of 4 weeks at home. One 
can also conceive a combination of the previous schemes. 
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What is NANIPER? 
The question of the mode of action of capsaicin in NANIPER cannot be answered without the 
answer to the question: "what is NANIPER?". As mentioned before NANIPER is probably 
not one disease but a collection of diseases inducing the same nasal symptoms. 
NARES and occult allergy 
One camlOt elaborate on the effect of capsaicin in NARES patients since there is no data on 
these patients. FurthemlOre due to the good response of these patients to local steroids there is 
simply no need for capsaicin therapy in NARES. The same argumentation applies for the 
subgroup of patients possibly suffering from an occult allergy. 
Chronic injlammation. 
Chronic inflammation can be the result of the underlying disorder in NANIPER. It is known 
that allergic rhinitis patients with complaints where an allergic infiltrate can be observed in 
the nasal mucosa exhibit a nasal hyperreactivity (48). Therefore it is reasonable to raise the 
possibility of "a disorder" inducing an inflammatory infiltrate in the nasal mucosa of 
NANIPER patients resulting in their nasal complaints. Vice versa it can also be argued that 
the underlying disorder such as the postulated over-active NANC system (13) is directly 
responsible for the nasal complaints and that an eventually noted increase in inflammatory 
cell densities in the nasal mucosa is seen as a consequence of the underlying disorder without 
having any relation with the nasal complaints. Fortunately we can short-circuit this discussion 
since we have showed that inflammatory cells are not involved in NANIPER. Capsaicin 
therefore does not exert its effect in NANIPER through modulation of inflammatory cells. 
Neurogenic imbalance 
The theory of a neurogenic dysfunction is very attractive and elegant. It appeals to the modem 
descartian medical professional since cause and consequence are neatly ordered. 
Unfortunately hard evidence is scarce. One of the firsts to suggest the involvement of the 
NANC-system in NANIPER was Lundblad in 1983 (49). However he extrapolated from the 
animal model. Lacroix in 1992 was able to show an increased concentration of neuropeptides 
in a group of non-allergic rhinitis patients (19), improvement of symptoms by local treatment 
of capsaicin giving a 50% reduction in CGRP-Li content in nasal biopsies (40), and a 
correlation between symptoms intensity and CGRP-Li concentration in nasal mucosa (50). 
Regrettably these patients were either abusing sympathico-mimetic nose-drops or underwent 
surgery for paranasal sinus pathology. Graf described an increase in hyperreactivity following 
the use topical decongestants (51). And so. it is very imaginable that the increase ofCGRP-Li 
levels is the result of an overactive peptidergic system induced by a suppressed sympathetic 
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system, or the result of chronic infection. In contrast, Wolff was recently unable to show a 
reduction of NANC-fibers in the nasal mucosa in NANIPER patients after successful 
capsaicin treatment (37). However his method of quantifying the NANC-fibers is not made 
clear. Fang reported on neuropeptide tissue concentrations and neuroendocrine ceB densities 
in normals and NANIPER patients. No significant differences were found. Unfortunately, in 
spite of elegant neuropeptide quantification methods, patients are simple characterized as 
suffering from chronic hypertrofic rhinitis (53). Hyperresponsiveness of mucosal elements to 
neuronal stimulation has been putatively cited as a pivotal mechanism in NANIPER. Sanieo 
was unable to show an increased (secretory) responsiveness to capsaicin provocation in a 
group of NANIPER patients and concludes that neurovascular involvement in NANIPER is 
unlikely (52). Unfortunately obstruction was not evaluated in this study. In our patients 
obstruction was the dominant complaint. Eberle was able to show a rhinomanometric 
increase in nasal flow after modulation of the neurovascular components of the nasal mucosa 
by capsaicin treatment, suggesting involvement of the neurovascular system in NANIPER. A 
recent study by Wilde showed an abnormal response to axillary pressure and isometric 
exercise in intrinsic rhinitis (NANIPER), perhaps due to relative nasal sympathetic 
hyposensitivity (24, 25). Since sensory efferent, cholinergic and adrenergic neural pathways 
are anatomically linked and interact a compensatory change (increase) in the sensory neural 
pathway (NANC-fibers) due to hyposensitivity of another neural (sympathetic) pathway is a 
plausible option. However in our own studies with capsaicin we were unable to show a 
change in overall neurogenic staining between placebo and capsaicin treatment in NANIPER 
patients. Nevertheless we feel that functional results prevail over morphological data. To 
conclude: it seems likely that capsaicin exerts its effect through a depletion of sensory 
neuropeptides either through atrophy of the NANC-system via neurotoxity (39) or through 
receptor modulation (37). Regrettably decisive data is missing. 
Dys- 01' hypel'- esthesia at the eNS level 
IfNANIPER patients are suffering from no more than a misguided perception due to a faulty 
interpretation of afferent signals originating in the nasal mucosa, than capsaicin is an ideal 
chemical that can either through atrophy or receptor modulation of the afferent neural system 
in the nasal mucosa trick the central nervous system into a "feel good" perception. The 
bandwidth of successful neural modulation is small. A total deafferentation of the c-afferent 
system, e.g. by applying a local anesthetic such as Xylocaine to the nasal mucosa, results in 
an increased perception of nasal blockage. Furthennore for a correction of a faulty perception 
suggesting a reduced nasal passage at eNS level an increase in afferent signals is required. 
This can be compared with the perception of an increased nasal flow after the consumption of 
menthol. Obviously, this train of thought is false if all the afferent signals responsible for the 
perception of nasal flow are generated by the myelinated C-afferent system. 
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CONCLUSIONS 
A well-defined group ofNANIPER patients was selected. 
NARES patients were not included in our group. This is probably the result of a good 
response to therapy in the first echelon. 
Patients with a typical allergic infiltrate in the nasal mucosa (despite negative allergy 
tests) constituted a maximum of3% of the study population 
Fluticasone propionate aqueous nasal spray (FPANS) does not reduce nasal 
complaints in NANIPER. 
Fluticasone propionate aqueous nasal spray (FPANS) does significantly reduce the 
normal inflanunatory cell densities in NANIPER. Tins has no clinical bearing. 
Inflammatory cells are not involved in NANIPER 
Capsaicin aqueous nasal spray significantly reduces nasal complaints in NANIPER 
patients. 
Capsaicin aqueous nasal spray does not affect inflammatory cell densities or 
inflammatory mediator concentrations in the nasal mucosa, 
The etiology ofNANIPER is still unclear. 
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Chapter 8 
Summary 
Samenvatting 

SUMMARY 
Chapter 1 contains a general introduction to the thesis. NANIPER is defined as a chronic 
nasal disorder of unknown pathogenesis. The epidemiology, pathogenetical models and 
treatment modalities of NANIPER are described. The key~questions of this thesis are 
presented. 
lu chapter 2 forty patients suffering of NANIPER were enrefully selected on the basis of 
inclusion and exclusion criteria proposed by Mygind and Weeke. Nasal biopsy specimens were 
taken in the patient group as well as a group often controls. Brush cytology was also taken in the 
NANIPER group. Inflammatory cells were identified and counted in the nasal mucosa with the 
use of immunohistochemical techniques and a panel of monoclonal antibodies. Eosinophils were 
studied with the use of HMKI3, RG2, and Giemsa. Mast cells were studied with antichymase 
(B7), anti-tryptase (G3) and toluidine blue. Sections were stained with IgE as well. There was no 
significant difference in the number of eosinophils, mast cells and IgE-positive cells between the 
two groups. Additionally in contrast with other reports, in sections that were double-stained with 
anti-chymase and anti-tryptase, single chymase positive cells were fOlmd. 
In chapter 3 mucosal inflammatory cell densities are correlated with nasal complaints in 
NANIPER. Some authors suggest inflammation of neurogenic or immunogenic nature as 
underlying disorder for NANIPER. We examined whether inflammatory cells are involved in 
the pathogenesis of NANIPER. Nasal biopsies were taken of sixty-five patients with 
significant nasal complaints and twenty controls without nasal complaints. Inflammatory cells 
were quantified, using monoclonal antibodies directed against lymphocytes, antigen 
presenting cells, eosinophils, mast cells, macrophages and monocytes. No significant 
differences were found, for any cell, between patients and controls. \Ve conclude that 
inflammatory cells are not involved in NANIPER 
In chapter 4 the efficacy of topical steroids on nasal complaints and the effect on mucosal 
cell densities are studied in a group of 65 NANIPER patients. Topical corticosteroids are the 
therapy of choice in non-allergic non-infectious perennial rhinitis (NANIPER). However, the 
efficacy of the steroid therapy in NANIPER is controversial, as is its mode of action. To our 
surprise, out of 300 patients initially diagnosed as suffering from NANIPER, only 65 patients 
with NANIPER reached threshold nasal symptom scores. Patients were randomized into four 
different treatment regimes. Placebo bi daily (BD) for 8 weeks, fluticasone 200 mg once daily 
(OD) and placebo OD for 8 weeks, fluticasone 200 mg OD and placebo' OD for 4 weeks 
followed by fluticasone 200 mg BD for 4 weeks, and fluticasone 200 mg (BD) for 8 weeks. A 
small decrease in nasal symptomatology was found which only reached significance for 
sneezing. A significant dose dependent decrease in immunocompetent cells was found in 
nasal biopsies obtained after 4 weeks, and after 8 weeks of treatment. We conclude that 
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topical corticosteroids do not significantly improve nasal symptoms in this group of selected 
NANIPER patients, even though a significant effect was seen on cells in the nasal mucosa. 
In Chapter 5 the efficacy of topical aqueous capsaicin spray in the treatment of NANIPER 
patients was studied. Several authors described capsaicin, the pungent substance in red 
pepper, as an efficacious therapy for non-allergic non-infectious perelmial rhinitis 
(NANIPER). Repeated capsaicin application induces peptide depletion and specific degenera-
tion of the umnyelinated sensory C-fibers in the nasal mucosa. \Ve performed a placebo (NaCI 
0.9%) controlled study with 25 NANIPER patients. Daily record charts and visual analogue 
scales (VAS) were used for clinical evaluation. Nasal lavages were obtained before, during, 
and after treatment. There was a significant and long-term reduction in the VAS scores in the 
capsaicin group. No significant difference was found between the placebo and capsaicin 
treated groups for the mean group concentrations of leukotriene (LT) CJD4/E4, prostaglandin 
D2 (pGD2), and tryptase. The levels of mast cell mediators, tryptase and POD2, and leukotrie-
nes, mediators derived from a variety of inflmmnatory cells, were low at baseline and 
comparable with levels observed in nasal lavages obtained from nomlais. As involvement of 
inflammation could not be demonstrated, it is not surprising that capsaicin has no effect on 
inflanunatory mediators. This suggests that inflammatory cells do not playa major part in the 
pathogenesis ofNANIPER. 
In Chapter 6 the long term effects of capsaicin spray on the nasal mucosa are studied. 
Capsaicin has been shown previously to reduce nasal complaints in patients with a non-allergic 
non-infectious perennial rhinitis. Proposed pathophysiologic mechanisms for non-allergic non-
infectious perennial rhinitis include a chronic inflammatory disorder of antigenic or neurogenic 
nature as well as the possibility of a functional neuronal disorder. We hypothesized that the 
benificial effect of capsaicin might be the result of a down regulation of intlmmnation (by a 
reduction ofinfiammatory cells) or through a modulation of neural tissue density. Patients were 
treated with either a placebo or capsaicin spray solution delivering 0.15 milligrams of capsaicin 
per nostril once every second or third day for a total of seven treatments. Both sides were treated 
each visit. Biopsies were taken before, 2 weeks after, 3 months after, mId 9 months after the 
treatment period. Inununohistochemical staining of the biopsy specimen was perfomled to 
ascertain the effect of treatment on immunocompetent cell densities (quantitative) and nernal 
tissue densities (semi-quantitative) in the nasal mucosa. Nasal complaints were significantly 
reduced in the capsaicin treated group. TIle nwnber of CD I +, CD25+, CD3+, CD68+, BMKI3+, 
IgE+, Tryptase+, and Chymase+ cells did not significantly differ between capsaicin and placebo 
group. No significant differences between both groups were found in pan-neurogenic staining of 
nasal mucosa using neurofilament and synaptophysine. Capsaicin aqueous nasal spray has been 
shown previously to reduce nasal complaints without affecting cellular homeostasis or overall 
neurogenic staining upto 9 months after treatment, furthermore inununocompetent cells are 
not involved in non-allergic non-infectious perennial rhinitis. 
98 
SAMENVATTING 
Hoofdstuk 1 bevat de algemene introduetie van dit proefschrift. NANIPER wordt 
gedefinieerd als een chrollische rhinopathie met een ollduidelijke pathogenese. De 
epidemiologie, bestaande pathogenetische modellen en behandelings-mogelijkheden van deze 
aalldoening worden besproken. De doelstellingen van dit proefschrift worden beschreven. 
In hoofdstuk 2 konden, gebruik makend van de in en exclusie criteria van Mygind en \Veeke 
40 patienten met NANIPER geselecteerd worden. Zowel in deze patientengroep als bij 10 
controles zander neusklachten werden neusslijmvliesbioptcn gellomen. In de NANIPER 
groep werd eveneens een neusbrush afgenomen. Met behulp van monoclonale antilichamen 
werden inflamrnatoire cellell gei'dentificeerd en gekwantificeerd in de biopten. Eosinofielen 
werden bestudeerd met behulp van BMK13, EG2 en Giemsa. MestceHen werden bestudeerd 
met behulp van anti~chymase. anti-tryptase en toluidine bl~uw. De coupes werden eveneens 
gekleurd met anti~ IgE. Er werd voor geen van de verschillende kleuringen significante 
verschillen gevonden. Verder werden in tegenstelling tot de bekende literatuur eukel 
chymase-positieve cellen gevonden ill coupes dubbelgekleurd met anti-chymase en anti-
tryptase. 
In hoofdsfuk 3 wordt onderzocht in hoeverre inflalllmatoire celIen betrokken zijn bij de 
neusklachten van NANIPER patienten. Inflammatie van neurogene dan wei inmlUIlogene aard 
wordt door sommige auteurs als het onderliggend Jijden van NANIPER gezien. Wij 
onderzochten of inflamIHatoire cellen betrokken zijn bij het ontstaan van NANIPER. Bij 65 
pati~nten, met voldoende neusklachten, en 20 controles zonder neusklachten werden biopten 
van het neusslijmvlies genom en. De aantallen lymfocyten, antigeenpresenterende ceHen, 
eosinofielen, macrofagen, monocyten en mestcellen werden bepaald met behulp van 
monoc1onale antilichamen. Er werden geen significante verschillen gevonden tussen pati~nten 
en controles. \Vij conc1uderen dat inflammatoire ceHen niet betrokken zijn bij NANIPER. 
In hoofdstuk 4 wordt de effectiviteit van locale steroiden bij de behandeling van neusklachten 
en het effect op inflammatoire in het neusslijmvlies bestudeerd. Lokale steroi'den zijn de 
therapie van keuze in NANIPER. De effectiviteit en het werkingsmechanisme van de 
steroi'den bij NANIPER zijn echter stof voor discussie. Tot onze verrassing bleken slechts 65 
van de 300 patienten, die aanvankelijk als NANIPER geboekt waren, voldoende neusklachten 
te hebben am aan onze inc1usie criteria tc kunnen voldoen. Deze 65 patienten werden 
gerandomiseerd in 4 vcrschillende behandelingsschema. Placebo twee maal daags (BD) 
gedurende 8 weken, FPANS 200 meg een maal daags (OD) en placebo (OD) gedurende 8 
weken, FPANS 200 meg OD en placebo OD gedurende 4 weken gevolgd door FP ANS 200 
meg BD gedurende 4 weken, en FPANS 200 meg gedurende 8 weken. Er werd een kleine 
afname van neusklachten gevonden die aIleen significant bleek voor niezen. Een significante 
dosis afllankelijke afname van het aantal illlmuuncompetente cellen werd gevonden na 4 en 8 
weken behandeling. \Vij concluderen dat locale steroi'den de lleusklachten van deze groep 
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streng geselecteerde patienten niet significant verbeterd ondanks een significante afhame van 
het aantal immuuncompetente cellen in het neusslijmvlies. 
In hoofdstuk 5 wordt het effect van capsaicine nevel op de neusklachten van NANIPER 
patienten en op ontstekingsmediatoren bestudeerd. Capsaicine wordt door verschillende 
auteurs beschreven als een effectief middel bij NANIPER. Herhaalde capsaicine applicaties 
induceren neuropeptide depletie en specifieke degeneratie van de niet gemyeliniseerde C-
afferente vezels in het neusslijmvlies. Bij 25 paticnten werd een placebo gecontroleerde studie 
verricht. Dagkaarten en visual analogue scales (V AS) werden gebnlikt voor de klinische 
evaluatie. Voor, na en gedurel1de de behandeling werden neuslavages verricht. Er werd een 
lang aanhoudende, significante vennindering van neusklachten gevondel1 in de met capsaicine 
behandelde groep. Er werd geen verschil gevondel1 tussen de gemiddelde groep concentraties 
van Ieukotrienen C4ID4/E4, prostaglandine D2, en tryptase voor de verschillende 
behandelingen. De concentraties van mest cel mediatoren, tryptase en prostaglandine D2, en 
leukotrienen, mediatoren afkomstig van verscheidcne inflammatoire cellen waren laag en 
vergelijkbaar met concentraties gevonden bij l10nnale con troles. Capsaicine had dan ook geen 
effect heeft op de ontstekingsmediatoren. Dit suggereert dat inflammatoire ceHen geen grote 
rol spelen in de pathogenese van NANIPER. 
In hoofdstuk 6 worden de lange termijl1 effecten van capsaicine nevel op het neusslijmvlies 
van NANIPER patienten onderzocht. De effectiviteit van capsaicine behandeling bij 
NANIPER werd in hoofdstuk 5 heschreven. Veronderstelde pathogenetische mechanismen 
omvatten een chronisch inflammatoire aandoening van antigene dan wei neurogeen origine 
alsmede een mogeJijke functionele neurogene aandoening. \Vij veronderstelden dat het 
gtlllstige effect van capsaicine bij NANIPER ontstaat ten gevolge van een vermindering van 
inflammatie (via een reductie van inflammatoire ceHen) of dankzij een vennindering van de 
dichtheid van zenuwweefsel in het neusslijmvlies. Patienten werden behandeld met placebo of 
met een waterige capsaicine oplossing waarbij 0.15 mg capsaicine per neusgat werd verneveld 
om de een of twee dagen met in totaal 7 behandelingen. Neusslijmvlies biopten werden 
genomen voor, 2 weken na, 3 maanden na en 9 maallden na behandeling. Coupes van deze 
biopten werden immunohistochemisch bewerkt zodat het effect van de behandeling op 
inflammatoire celdichtheid (kwantitatief) en zenuwweefsel dichtheid (semi-kwantitatief) 
bepaald konden worden. Het gUllstige effect van capsaicine is reeds in hoofdstuk 5 
beschreven. Er werd geen verschil gevonden in de mediane aantallen van CDl+, CD25+, 
CD3+, CD68+, BMKI3+, igE+, Tryptase+ en Chymase+ cellen ttlssen de placebo en de met 
capsaicine behandelde groep. Ook met behulp van de neuromarkers "neurofilament" en 
"synaptofysine" konden geen verschillen worden aangetoond. Capsaicine heeft een gunstig 
effect op de neusklachten bij patlenten met NANIPER. Dit resulteert niet in een meetbaar 
effect op inflammatoire cellen of zenuwwecfsel dichtheid in het neusslijmvlies. 
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Figure 1 a-c. Serial sections of nasal mucosal biopsies. la Nasal mucosa stained with anti-
chymase. Ib Nasal mucosa stained with anti-tryptase. Ie Nasal mucosa stained with anti-
chymase (blue) and anti-tryptase (red). The double stained cells can be clearly discemed. Single-
chymase positive cell marked (c), single-tryptase positive cells marked (t), double positive cells 
marked (d).TIle sections are slightly counterstained with hematoxylin and eosin (magnification 
160 x). 
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Figure 2. Lymphocytes in the nasal mucosa (CD3 +). The epithelium, basal membrane, and 
lamina propria can be distinguished. Positive cells stain red. Lymphocytes are abundantly 
present in both layers (magnification 160 X). 
Figure 3. Mast ceIls in the nasal mucosa (tryptase+). The different mucosal layers can be 
distinguished. Mast cells are not present in the epithelium, but arc frequently present in the 
lamina propria (magnification 160 X). 
Figure 4a and b. 
Figure Sa and b. 
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Synaptophysine in the nasal mucosa (magnification 160 X). 
4a. Strong staining. Axial, transversal and longitidinal cut fibers can be 
distinguished. No signal is seen in the epithelium 
4b. Weak staining. Mostly axial cut fibers are seen. 
Neurofilament in the nasal mucosa (magnification 160 X). 
Sa. Strong staining. Mostly longitudinal cut fibers are seen in both 
the epithelium and lamina propria. 
5b. Weak staining. Some longitudinal ellt fibers can be 
distinguished. 
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Figure 6. Sections of nasal mucosa of patients and controls. Eosinophils (A, B), 19E positive 
(C, D) and CD4 (G, H) and CDS (E, F) positive cells are shown. No significant differences 
were found between both groups for the various cells. (A, C, E, G: NANIPER patients; B, D, 
F, H: CONTROLS; magnification 160 X) 
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DANKWOORD 
De in dit proefschrift heschreven onderzoeken werden verrieht binnen de afdelingen Keel-
neus-oorheelkunde vall het Leyenburg Zickenhuis, Den Haag en het Dijkzigt Ziekenhuis, 
Rotterdam en de afdelingen Immunologic en het Keel-neus-oorheelkundig research 
laboratorium van de Erasmus Ulliversiteit Rotterdam. 
Ik wil graag eenieder bedanken die me geholpen heef! bij de totstandkoming van dit 
proefschrift. Een aantal van hen wil ik hief met name nocmcn. 
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heeft U het dreigement dat mijn opleiding minstens 10 jaar zou gaan durcn niet uitgevoerd. 
Dr. W.J. Fokkens. Beste Wytske, ik ben je zeer erkentelijk voor je begeleiding en je 
aandeel in mijn varming tot KNO-onderzoeker. Je hebt de gave om dingen scherp te bekijken. 
Dr. E. Rijntjes. Beste Evert, allereerst dank, dat je me uit de klauwen van de minister 
gered hebt. Verder heb ik in het Leyenburg de KNO "ontdekt". Jouw omgang met patienten is 
bijzonder stimulerend. Ik heb een perfecte wetenschappelijke en geneeskundige start bij je 
kunnen maken. 
Prof. Dr. lH. de Jongste. Beste Johan, de snelheid en het enthousiasme waarmee je het 
manuscript hebt beoordeeld, doet vermoeden dat we veel en plezierig zuIlen samenwerkcn. 
Prof Dr. H.C. Hoogsteden. Beste Henk, zeer veel dank voor je razendsnelle hulp. 
Prof. Dr. A. Anggard. Dear professor Anggard, I would like to thank you very much 
for your stimulating words during various international meetings. I'm honored that you are 
prepared to come to Holland to "join the opposition". I look forward to the next meetings. 
Dr. R. Gerth van Wijk. Beste Roy, niet aileen heb je een belangrijk aandeel gehad in 
de capsaicine onderzoeken, ook heb je me geholpen met de puntjes op de "i" van de discussie. 
Ik waardeer het enorm dat je jezelf op 23 oktober hebt willen vrijmaken. 
EUy van Schaik. Beste EUy, een dankwoord zou niet compleet zijn als jij niet vermeld 
zou zijn. Je hebt je het vuur uit de sloffen gelopen om patienten te verzamelen, motiveren en 
behandelen. 
Jeroen van Rijswijk. Beste Jeroen, ik vind het geweldig hoe jij je voor eenieder, in 
voor jou toch zeer moeilijke tijden, inzet. Ik hoop dat ik voor jOll hetzelfde terog kan doen. 
IINema problema" 
Alex KleinJan en Lisanne Severijnen. Jullie is nooit wat teveel; de dilizenden coupes, 
kleuringen en een groot gedeelte van de teliingen. En natuurlijk de goede ideeen. Petje af. 
Ewout Baarsma en Cock Hoogerwerf. Hartelijk dank voor het stimuleren van jullie 
patienten om aan de onderzoeken mee te doen. 
Paul Mulder. Beste Paul, met jot! (soms onnavolgbare) kijk op de data, heb je mij 
menig maal de relevantie van significantie doen illzien. 
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Tom Godthelp. Beste Tom, jij was mijn laboratorium vraagbaak in de eerste jaren. Je 
veelomvattende gezellige persoonlijkheid zal zeker tot Zijll reeht komen in het "Brabantse". 
Adriaao Holm. Beste Adriaao, ik begrijp niet waarom ze ons voortdurend venvisselen. 
Jij wei? 
Hans Hoeve. Capo di tuti eapi van het Sophia, ik werk erg graag met je samen. 
De patienten. Zonder jullie was dit bockje er niet geweest. Biopten, bntshes, bezoeken; 
placebo, peper, patientellboekjes; het was allemaal gcen enkel probleem. Heel veel dank. 
De piih, de moh en fratel. Bedankt dat jullie BS, op gezette momenten, de spiegel 
voorhouden. 
Maja, moja prva i poslednja Ijubav. 
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